Ology Bioservices, Inc.   Proprietary  
 A Phase 1 , Randomized, Double -Blind, Dose Escalation Study to Evaluate the 
Safety and Pharmacokinetics of a Single IM Dose of G03-52 -01 vs Placebo in 
Adult Subjects.  
 
Ology Bioservices  Protocol Number:  G03 -52-01.001  
 
IND Sponsor:  Ology Bioservices, Inc.  
 
Principal Investigator: Cassandra Key, MD  
Medical Monitor: Uma Arumugam , MD  
 
  
Version 3.0 
September 7, 2021  
 
Protocol: G03-52-01.001 Version 3.0 
 September 7, 2021 
Ology Bioservices, Inc.  2 Proprietary  
 STATEMENT OF COMPLIA NCE  
The study will be carried out in accordance with Good Clinical Practices (GCP) as required by 
the following: 
• United States Code of Federal Regulations (CFR) applicable to clinical studies (45 CFR Part 46; 21 CFR Part 50, 21 CFR Part 54, 21 CFR Part 56, and 21 CFR Part 312); 
• International Conference on Harmonization (ICH) E6; 62 Federal Register 25691 (1997); 
• Department of Defense (DOD ) Clinical Terms of Award, as applicable.  
• Applicable Laws and Regulations  
Compliance with these standards provides public assurance that the rights, safety and well- being 
of study subjects are protected, consistent with the principles that have their origin in the Declaration of Helsinki.  
All key personnel (all individuals responsible for the design and conduct of this study) have completed Human Subjects Protection Training. 
Protocol: 003-52-01.00 I 
Signature Page Version 3.0 
September 7, 2021 
The signature below constitutes the approval of this protocol and the attachments and provides 
the necessary assurances that this trial will be conducted according to all stipulations of the 
protocol, including all statements regarding confidentiality, and according to local legal and 
regulatory requirements and applicable United States of America (US) federal regulations and 
ICH guidelines. 
Site Investigator: Cassandra Key, MD I Principal Investigator 
Signature: 
Date: 
Sponsor: John Abernethy, MD I Medical Director 
Signature: 
Date: 
Ology Bioservices, Inc. 3 Proprietary 
Protocol: G03-52-01.001 Version 3.0 
 September 7, 2021 
Ology Bioservices, Inc.  4 Proprietary  
 TABLE OF CONTENTS  
STATEMENT OF COMPLIA NCE  .................................................................................................2  
TABLE OF CONTENTS  .................................................................................................................4  
LIST OF ABBREVIATION S ..........................................................................................................9  
SUMMARY OF CHANGES FOR VERSION 3.0  ........................................................................13  
SUMMARY OF CHANGES FOR VERSION 2.0  ........................................................................28  
PROTOCOL SUMMARY .............................................................................................................32  
1. KEY ROLES  ..............................................................................................................37  
2. BACKGROUND INFORMATI ON AND SCIENTIFIC RATIONALE  ...................37  
2.1. Background Information .............................................................................................39  
2.1.1.  Introduction .................................................................................................................39  
2.1.2.  Currently Available Treatments  .................................................................................39  
2.1.3.  G03-52-01 Development ............................................................................................40  
2.1.4.  Public Readiness and Emergency Preparedness Act  ..................................................41  
2.2. Rationale For Use of G03 -52-01 ................................................................................42  
2.3. Potential Risks and Benefits  .......................................................................................43  
2.3.1.  Potential Risks  ............................................................................................................43  
2.3.2.  Known Potential Benefits ...........................................................................................44  
3. OBJECTIVES  .............................................................................................................44  
3.1. Study Objectives  .........................................................................................................44  
3.2. Study Outcome Measures ...........................................................................................45  
3.2.1.  Primary Endpoints ......................................................................................................45  
3.2.2.  Secondary Endpoints ..................................................................................................45  
4. STUDY DESIGN  .......................................................................................................45  
4.1.1 Subject Incl usion Criteria  .....................................................................................................47  
4.1.2 Subject Exclusion Criteria ....................................................................................................48  
4.2 Treatment Assignment Procedures ..........................................................................................50  
4.2.1 Randomization Procedures ...................................................................................................50  
4.2.2 Masking Procedures ..............................................................................................................51  
4.2.3 Reasons for Withdrawal ........................................................................................................51  
4.2.4 Handling of Withdrawals ......................................................................................................52  
4.2.5 Lost to Follow-up ..................................................................................................................52  
Protocol: G03-52-01.001 Version 3.0 
 September 7, 2021 
Ology Bioservices, Inc.  5 Proprietary  
 4.2.6 Termination of Study ............................................................................................................52  
5. STUDY PRODUCTS  .................................................................................................52  
5.1. Description of Study Products ....................................................................................52  
5.2. Acquisition  ..................................................................................................................52  
5.3. Formulation , Packaging, and Labeling .......................................................................53  
5.4. Product Storage and Stability .....................................................................................53  
5.5. Dosage, Preparation and Administration ....................................................................53  
5.6. Accountability Procedures for the Study Products .....................................................54  
5.7. Assessment of Subject Compliance with Study Product ............................................54  
5.8. Concomitant Medications ...........................................................................................54  
6. STUDY PROCEDURES  ............................................................................................55  
6.1. Medical H istory  ..........................................................................................................55  
6.2. Physical Examination  .................................................................................................55  
6.3. Vital Signs  ..................................................................................................................56  
6.4. Electrocard iogram  .......................................................................................................56  
6.5. Laboratory Evaluations ...............................................................................................56  
6.5.1.  Screening Laboratory Tests  ........................................................................................56  
6.5.1.1.  Viral Serology Testing  ................................................................................................56  
6.5.2.  Safety Laboratory Tests  ..............................................................................................57  
6.5.3.  Hypersensitivity Panel  ................................................................................................58  
6.6. Special Assays or Procedures  .....................................................................................58  
6.6.1.  Pharmacokinetic Assay  ...............................................................................................58  
6.6.2.  Anti-Drug Antibody Assay  .........................................................................................58  
6.6.3.  Future Use ...................................................................................................................58  
6.6.4.  Specimen Preparation, Handling, and Shipping .........................................................58  
7. STUDY SCHEDULE  .................................................................................................61  
7.1. Visit 1: Screening (Day -28 to Day -3) .......................................................................61  
7.2. Visit 2: Baseline (Day 0)  ............................................................................................62  
7.3. Visit 3: Out- patient Follow -up (24 hours/Day 1) .......................................................63  
7.4. Visit 4: Out- patient follow -up Visit (48 hours/Day 2) ...............................................63  
7.5. Visit 5: Out- patient Follow -up (72 hours) Cohorts 1-3 ..............................................64  
7.6. Visit 6: Out- patient Follow -up (Day 4) ......................................................................64  
Protocol: G03-52-01.001 Version 3.0 
 September 7, 2021 
Ology Bioservices, Inc.  6 Proprietary  
 7.7. Visit 7: Out- patient Follow -up (Day 8± 1) .................................................................64  
7.8. Visit 8: Out- patient Follow -up (Day 15± 1) ...............................................................65  
7.9. Visit 9: Out- patient Follow -up (Day 30 ± 1) ..............................................................65  
7.10.  Visit 10: Out- patient Follow -up (Day 45± 3) .............................................................66  
7.11.  Visit 11: Out- patient Follow -up (Day 60 ± 3) ............................................................66  
7.12.  Visit 12: Out- patient Follow -up (Day 90±3) ..............................................................67  
7.13.  Visit 13: Final Visit / Early Termination Visit for Cohorts 1 -3 (Day 120±3)  / 
Cohort 4 (Day 120±3) .................................................................................................67  
7.14.  Visit 14: Final Visit/ Early Termination for Subjects in Cohort 4  (Day 
180±3) .........................................................................................................................68  
7.15.  Unscheduled Visit .......................................................................................................68  
8. ASSESSMENT OF SAFETY  .....................................................................................69  
8.1. Specification of Safety Parameters  .............................................................................69  
8.2. Methods and Timing for Assessing, Recording, and Analyzing Safety Parameters  ...................................................................................................................70
 
8.2.1.  Adverse Events  ...........................................................................................................70  
8.2.2.  Relationship to Study Product ....................................................................................70  
8.3. Reporting Procedures ..................................................................................................71  
8.3.1.  Adverse Events:  ..........................................................................................................71  
8.3.2.  Serious Adverse Events ..............................................................................................71  
8.3.3.  Regulatory Reporting ..................................................................................................72  
8.3.4.  Reporting of Pregnancy ..............................................................................................73  
8.4. Type and Duration of Follow-up of Subjects after Adverse Events ...........................73  
8.5. Halting Rules  ..............................................................................................................73  
8.5.1.  Halting  Criteria for the Study  .....................................................................................73  
8.5.2.  Dose Escalation Halting Criteria  ................................................................................73  
8.5.3.  Evaluation of Dose Escalation ....................................................................................74  
8.6. Safety Oversight  .........................................................................................................74  
8.6.1.  Indep endent Safety Monitor (ISM) ............................................................................74  
8.6.2.  ICON Medical Monitor ..............................................................................................74  
8.6.3.  Ology Bioservices Medical Monitor ..........................................................................74  
8.6.4.  Safety Review Committee (SRC)  ...............................................................................74  
9. CLINICAL MONITORING .......................................................................................75  
Protocol: G03-52-01.001 Version 3.0 
 September 7, 2021 
Ology Bioservices, Inc.  7 Proprietary  
 9.1. Site Monitoring Plan  ...................................................................................................75  
10. STATISTICAL CONSIDERATIONS  .......................................................................75  
10.1.  Sample Size Considerations .......................................................................................75  
10.2.  Planned Interim Analyses ...........................................................................................76  
10.3.  Final Analysis Plan  .....................................................................................................76  
10.3.1.  Analysis Populations ..................................................................................................76  
10.3.2.  Demographics and Baseline Characteristics  ...............................................................76  
10.3.3.  Safety Analysis Plan  ...................................................................................................76  
10.3.3.1.  Adverse and Serious Adverse Events .........................................................................76  
10.3.3.2.  Additional Safety Analyses  ........................................................................................77  
10.3.4.  PK Analysis Plan  ........................................................................................................77  
10.3.5.  Immunogenicity  ..........................................................................................................77  
10.3.6.  Missing values and outliers ........................................................................................78  
11. SOURCE DOCUMENTS AND ACCESS TO SOURCE 
DATA/DOCUMENTS  ...............................................................................................79  
12. QUALITY CONTROL AND QUALITY ASSURANCE  .........................................79  
13. ETHICS/PROTECTION OF  HUMAN SUBJECTS  ..................................................80  
13.1.  Ethical Standard  ..........................................................................................................80  
13.2.  Institutional Review Board  .........................................................................................80  
13.3.  Informed Consent Process ..........................................................................................80  
13.3.1.  Informed Consent .......................................................................................................80  
13.4.  Exclusion of Women, Minorities, and Children (Special Populations) ......................81  
13.5.  Subject Confidentiality  ...............................................................................................82  
13.6.  Study Discontinuation ................................................................................................82  
13.7.  Future Use of Stored Specimens .................................................................................82  
14. DATA HANDLING AND RECORD KEEPING  ......................................................82  
14.1.  Data Management Responsibilities  ............................................................................83  
14.2.  Data Capture Methods  ................................................................................................83  
14.3.  Types of Data  ..............................................................................................................83  
14.4.  Timing/Reports  ...........................................................................................................83  
14.5.  Study Records Retention ............................................................................................83  
14.6.  Protocol Deviations ....................................................................................................84  
Protocol: G03-52-01.001 Version 3.0 
 September 7, 2021 
Ology Bioservices, Inc.  8 Proprietary  
 15. PUBLICATION POLICY  ..........................................................................................84  
16. LITERATURE REFERENCES ..................................................................................85  
 
  
 
  
Protocol: G03-52-01.001 Version 3.0 
 September 7, 2021 
Ology Bioservices, Inc.  9 Proprietary  
 LIST OF ABBREVIATION S 
ADA  Anti-Drug Antibody  
AE Adverse Event/Adverse Experience  
ALT  Alanine aminotransferase  
AST  Aspartate aminotransferase  
AUC  Area Under the Curve  
BMI  Body Mass Index  
BoNT  Botulinum Neurotoxin  
BP Blood Pressure  
Bpm  Beats per Minute  
BUN  Blood Urea Nitrogen  
CAR  Clinical Agents Repository  
CBC  Complete Blood Count  
CDC  Center s for Disease Control  and Prevention  
CFR  Code of Federal Regulations  
CHO  Chinese hamster ovary  
Cmax Maximum Plasma Titer/Concentration  
CPM  Clinical Project Manager  
CROMS  Clinical Research Operations and Management Support  
DCC  Data Coordinating Center  
DHHS  Department of  Health and Human Services  
DMP Data Management Plan  
DOD  Department of Defense  
eCRF  Electronic Case Report Form  
ECG  Electrocardiogram  
EDC  Electronic Data Capture  
ECL A Electrochemiluminescence  Assay  
ELISA  Enzyme -Linked Immunosorbent Assay  
FDA  Food and Drug Administration  
FDAAA  Food and Drug Administration Amendments Act  
Protocol: G03-52-01.001 Version 3.0 
 September 7, 2021 
Ology Bioservices, Inc.  10 Proprietary  
 FESAP  Federal Experts Advisory Panel  
FWA  Federal  Wide Assurance  
GCP  Good Clinical Practice  
GLP  Good Laboratory Practice  
Gm Gram  
gm/dL  Grams per Deciliter  
HBAT  Heptavalent Equine Antitoxin  
HBsAg  Hepatitis B Surface Antigen  
HCG  Human Chorionic Gonadotropic Hormone  
HCV  Hepatitis C Virus  
HED  Human Equivalent Dose  
HEENT  Head, Eyes, Ears, Nose and Throat  
HIV Human Immunodeficiency Virus  
HR Hear t Rate 
Hr/hr  Hour  
HRPO  Human Research Protections Office  
HRSA  Health Resources and Services Administration  
ICH International Conference on Harmonisation  
IDES  Internet Data Entry System  
IEC Independent or Institutional Ethics Committee  
IgG Immunoglobulin G  
IHC Immunohistoch emistry  
IM Intramuscular  
IND Investigational New Drug  
IP Intraperitoneal  
IRB Institutional Review Board  
ISM Independent Safety Monitor  
ITT Intention -To-Treat  
IUDs  Intrauterine Contraceptive Device  
IV Intravenous  
Protocol: G03-52-01.001 Version 3.0 
 September 7, 2021 
Ology Bioservices, Inc.  11 Proprietary  
 KG Kilogram  
LLN  Lower Limit of Normal  
mAbs/mAb  Monoclonal Antibodies  
MedDRA Medical Dictionary for Regulatory Activities  
mEq/L  Milliequivalent per Liter  
Mg/mg  Milligram /milligram  
mg/dl  Milligram per Deciliter  
Ml/mL  Milliliter  
Mm/mm  Millimeter  
mmHg  Millimeters of Mercury  
MNA  Battelle Mouse Neutralization Assay  
MOP  Manual of Procedures  
MPA  Mouse Potency Assay  
MRSD  Maximum Recommended Starting Dose  
N Numbe r  
NIAID  National Institute of Allergy an d Infectious Diseases  
NIH National Institutes of Health  
NLM  National Library of Medicine  
NOAEL  No-Observed -Adverse -Effect -Level  
NSAIDS  Nonsteriodal Anti-Inflammatory Drugs  
OHRP  Office for Human Research  Protections  
OTC  Over the Counter  
PE Physical Examination  
PI Principal Investigator  
PK Pharmacokinetic(s)  
PR PR Interval -Standard ECG Terminology  
PREP  Public Readiness and Emergency Preparedness  
PT Prothrombin Time  
PTT Partial Thromboplastin Time  
PVG  Pharmacovigilance Group  
Protocol: G03-52-01.001 Version 3.0 
 September 7, 2021 
Ology Bioservices, Inc.  12 Proprietary  
 PVSS  Pharmacovigilance Safety System  
RBC/HPF  Red Blood Cells per High -Power Field  
SAE  Serious Adverse Event  
SRC  Safety Review Committee  
SOP Standard Operating Procedure  
Tmax Time to Maximum Concentration  
TTD  Time to Death  
µg Microgram  
ULN  Upper Limit of Normal  
WBC  White Blood Count  
 
  
Protocol: G03-52-01.001 Version 3.0 
 September 7, 2021 
Ology Bioservices, Inc.  13 Proprietary  
 SUMMARY OF CHANGES FOR VERSION 3 .0 
 
Version 2.0  Version 3.0  Reason for change  
Page 17: Protocol Summary 
Population = 30 
Study Duration = 8 months Protocol Summary 
Population = 40 
Study Duration = 10 months Additional Cohort added with extended follow-up period. 
Page 17: Protocol Summary,  
Subject Parti cipation  
Subjects in all cohorts will participate approximately 150 days (up to 28-day screening, 12-hour inpatient stay, up to 120 days outpatient follow-up) 
  Protocol Summary,  
Subject Participation  
Subjects in cohorts 1- 3 will 
participate approximately 150 
days (up to 28-day screening, 
12-hour inpatient stay, up to 120 days outpatient follow-up) 
Subjects in cohorts 4 will 
participate approximately 210 
days (up to a 28-day screening, 12-hour inpatient stay, up to 180-day outpatient follow-up) Additional Cohort added with extended follow-up period. 
Page 17 -18: Protocol 
Summary,  
Study Outcome Measures Secondary Endpoints:  
Pharmacokinetic samples will 
be tested by MNA at pre-dose and on Days 4, 30, 60, 90, and 120  
The assessment of Cmax, 
Tmax , half- life (α and β), 
MRT and AUC(0 -t) for each of 
the monoclonal antibodies of G03-52-01 as measured by a 
validated electrochemiluminescence assay (ECLA) or an enzyme-linked immunosorbent assay (ELISA).  Protocol Summary,  
Study Outcome Measures Secondary Endpoints:  
Pharmacokinetic samples will 
be tested by MNA at pre-dose and on Days 4, 30, 60, 90, and 120 for cohorts 1-3.   
Pharmacokinetic samples will 
be tested by MNA  at pre-dose  
and on Days 4, 30, 45, 60, 90, and 120 for cohort 4. 
The assessment of Cmax, Tmax, half -life (α and β), MRT 
and AUC(0 -t) for each of the 
monoclonal antibodies of G03-52-01 as measured by a 
validated 
electrochemiluminescence Additional Cohort added with extended follow-up period. 
Protocol: G03-52-01.001 Version 3.0 
 September 7, 2021 
Ology Bioservices, Inc.  14 Proprietary  
 Pharmacokinetic samples will 
be tested by ECLA or ELISA 
at pre-dose, 2, 4, 8, 24, 48, and 72 hours post injection, and on Days 4, 8, 15, 30, 45, 60, 90, and 120  
Samples collected to evaluate presence of anti -drug 
antibodies (ADA) collected for all cohorts. 
Samples will be tested for 
ADA at pre -dose and on Days 
15, 30, 45, 60, 90, and 120  assay (ECLA) or an enzyme -
linked immunosorbent assay (ELISA).  
 Pharmacokinetic samples will be tested by ECLA or ELISA at pre-dose, 2, 4, 8, 24, 48, and 72 
hours post injection, and on Days 4, 8, 15, 30, 45, 60, 90, and 120 for cohorts 1-3.    Pharmacokinetic samples will be tested by ECLA or ELISA at pre-dose, 6 hours post dose, 
and on Days 1, 2, 4, 8, 15, 30, 45, 60, 90, 120, and 180 for cohort 4.   Samples collected to evaluate presence of anti -drug 
antibodies (ADA) collected for all cohorts.  Samples will be tested for A DA 
at pre-dose and on Days 15, 30, 45, 60, 90, and 120 for cohorts 1-3.   
Samples will be tested for ADA 
at pre-dose and on Days 45, 60, 90, 120 and 180 for cohort 4.  
Page 18: Protocol Summary,  
Estimated Time to Complete Enrollment:   Approximately 3 months Protocol Summary,  
Estimated Time to Complete Enrollment:   Approximately 5 months 
  
Protocol: G03-52-01.001 Version 3.0 
 September 7, 2021 
Ology Bioservices, Inc.  15 Proprietary  
 Page 18: Protocol Summary, 
Description of Study Design: 
A Phase 1, randomized, 
double-blind, placebo-controlled dose escalation trial of three dose cohorts of 10 subjects: (A: 10mg, B: 25mg, C: 50mg)           Protocol Summary, Description 
of Study Design: 
A Phase 1, randomized, double-blind, placebo-controlled dose escalation trial of four dose 
cohorts as outlined below: 
• Cohort 1: 10 mg IM injection (8 active, 2 placebo)  
• Cohort 2: 25 mg IM injection (8 active, 2 placebo)  
• Cohort 3: 50 mg IM 
injection (8 active, 2 
placebo)  
• Cohort 4: 100mg IM injection (8 active, 2 placebo)  
 Added cohort 4 
Page 18 -19: Protocol 
Summary, Description of Study Design  
 Dose escalation will not occur until safety data through Day 8 is reviewed by the Safety Review Committee (SRC) composed of the Principal Investigator (PI), Ology Bioservices  Medical Monitor, 
and the DOD Medical Monitor. Objective dose-escalation criteria and safety evaluations will be utilized.  Protocol Summary, Description 
of Study Design 
 
Dose escalation will not occur until safety data through Day 8 is reviewed by the Safety Review Committee (SRC) composed of the Principal Investigator (PI), Ology Bioservices Medical Monitor, and the ICON Medical Monitor. Objective dose-escalation criteria and safety evaluations will be utilized. A SRC meeting will be held at any time durin g the course of 
the study if halting criteria are 
met or safety concerns arise.   Revise to include which Medical Monitors will attend the SRC and when the SRC meetings will occur.  
Page 19: Protocol Summary, 
Description of Study Design 
The study will cons ist of a 
twenty -eight -day screening 
period and 12-hour clinic stay.  Follow- up visits will occur at 
24 hours, 48 hours, and 72 Protocol Summary, Description 
of Study Design 
 
The study will consist of a twenty -eight -day screening 
period and 12-hour clinic stay.  
Follow -up visits will occur at Additional follow-up visits for cohort 4 added  
Protocol: G03-52-01.001 Version 3.0 
 September 7, 2021 
Ology Bioservices, Inc.  16 Proprietary  
 hours post dose and on Days 4, 
8, 15, 30, 45, 60, 90, and 120 
for all cohorts. 24 hours, 48 hours, and 72 
hours post dose and on Days 4, 8, 15, 30, 45, 60, 90, and 120 for cohorts 1-3. 
 Follow -up visits 
for subjects in  cohort 4 will 
occur on Days 1, 2, 4, 8, 15, 30, 45, 60, 90, 120, 150 and 180. 
 
Page 19: Protocol Summary, 
Description of Study Design 
Subjects will be screened for Human Immunodeficiency Virus (HIV), Hepat itis B 
surface antigen ( HBsAg), and 
antibody to Hepatitis C virus (HCV), drugs and alcohol.  Safety parameters include physical examination, 12- lead 
Electrocardiogram (ECG), vital signs, and clinical laboratory values to include: Complete Blood Count (CBC) with differential, comprehensive metabolic panel, and urine dipstick for blood, glucose and protein. Page 33: Protocol Summary, 
Description of Study Design 
 
Subjects will be screened for Human Immunodeficiency Virus (HIV), Hepatitis B surface antigen ( HBsAg), and 
antibody to Hepatitis C virus (HCV), drugs and alcohol.  Safety parameters include physical examination, 12- lead 
Electrocardiogram (ECG), vital signs, and clinical laboratory values to include: Complete Blood Count (CBC) with differential, comp rehensive 
metabolic panel, and urine dipstick for protein, blood, and 
glucose with reflex microscopy.   
 Added reflex microscopy 
Page 19: Protocol Summary, 
Description of Study Design 
 
Pharmacokinetic ( PK) samples 
will be drawn at pre-dose, 2, 4, 
8, 24, 48, and 72 hours post dose and on days 4, 8, 15, 30, 45, 60, 90, and 120.  PK samples will be tested by the Battelle Mouse Neutralization Assay (MNA) for serotypes A and B at pre-dose and on days 4, 30, 90, and 120 for all Protocol Summary, Description 
of Study Design 
 
Cohorts 1- 3:  Pharmacokinetic 
(PK) samples will be drawn at 
pre-dose, 2, 4, 8, 24, and 48, 
and 72 hours post dose and on days 4, 8, 15, 30, 45, 60, 90, and 120.  PK samples will be tested by the Battelle Mouse Neutralization Assay (MNA) for serotypes A and B at pre-dose and on days 4, 30, 60, 90, 
and 120.  PK samples will be Additional Cohort added with extended follow-up period. 
Protocol: G03-52-01.001 Version 3.0 
 September 7, 2021 
Ology Bioservices, Inc.  17 Proprietary  
 cohorts.  PK samples will be 
tested by ECLA or ELISA at 
pre-dose, 2, 4, 8, 24, 48, and 
72 hours  post dose and on days 
4, 8, 15, 30, 45, 60, 90, and 
120 for all cohorts.  Samples will be tested for anti- drug 
antibodies (ADA) at pre-dose and days 15, 30, 45, 60, 90, and 120.  A Safety Review Committee (SRC) meeting will be held if halting criteria are met or safety concerns arise.  tested by ECLA or ELISA at 
pre-dose, 2, 4, 8, 24, 48, and 72 
hours  post dose and on days 4, 
8, 15, 30, 45, 60, 90, and 120.  Samples will be tested for anti-drug antibodies (ADA) at pre-dose and days 15, 30, 45, 60, 90, and 120. Cohort 4:  Pharmacokinetic (PK) samples 
will be drawn at pre-dose, 6hours post dose, and on days 1, 2, 4, 8, 15, 30, 45, 60, 90, 120, and 180.  PK samples will be tested by the Battelle Mouse Neutralization Assay (MNA) for serotypes A and B at pre-dose, and on days 4, 30, 45, 60, 90, and 120. PK samples will be tested by ECLA o r ELISA at 
pre-dose, 6 hours post-dose and 
on days 1, 2, 4, 8, 15, 30, 45, 60, 90, 120, and 180.  Samples will be tested for anti- drug 
antibodies (ADA) at pre-dose and days 45, 60, 90, 120, and 180. 
Page 20: Schematic of Study Design  
 Schematic of Study Design  
Added cohort 4 to chart design Revised to show addition of Cohort 4  
Section 1 Key Roles: 
Ology Bioservices Medical 
Monitor 
John.abernethy@ologybio.com Section 1 Key Roles:   Ology Bioservices  Medical 
Monitor John.abernethy@resilience.com  Update contact information 
Page 25, Section 2.2 Rationale 
for Use of G03 -52-01  
Doses will escalate to 25 mg and then to 50 mg provided 
there are no safety concerns. Section 2.2 Rationale for Use of G03-52-01  
Doses will escalate to 25 mg and then to 50 mg provided 
there are no safety concerns. Added rational e for escalation 
to 100 mg dose  
Protocol: G03-52-01.001 Version 3.0 
 September 7, 2021 
Ology Bioservices, Inc.  18 Proprietary  
 The nonclinical IND -enabling 
toxicology st udies were 
designed to support this 
clinical design with intramuscular route of administration.
 The nonclinical IND -enabling 
toxicology studies were designed to support this clinical design with intramuscular route of administration.  Based on data received from the Day 60 blinded interim safety and PK analysis, it was determined to escalate to 100 mg single dose.  
Page 29, Section 3.2.2 
Secondary endpoints 
The pharmacokinetic assessment of Cmax, Tmax and AUC(0 -t) as measured by 
the validated Battelle Mouse Neutralization Assay (MNA) for serotypes A and B 
Pharmacokinetic samples will 
be tested by MNA at pre-dose and on Days 4, 30, 60, 90, and 120  
   The assessment of Cmax, 
Tmax, half -life (α and β), 
MRT, and AUC(0- t) for each 
of the monoclonal antibodies of G03-52- 01 as measured by a 
validated electrochemiluminescence assay (ECLA) or validated enzyme -linked immunosorbent 
assay (ELISA).  
Pharmacokinetic samples will be tested by ECLA or ELISA at pre-dose, 2, 4, 8, 24, 48, and 
72 hours post injection, and on Section 3.2.2 Secondary 
endpoints 
The pharmacokinetic assessment of Cmax, Tmax and AUC(0 -t) as measured by the 
validated Battelle Mouse Neutralization Assay (MNA) for serotypes A and B 
Pharmacokinetic samples will 
be tested by MNA at pre-dose and on Days 4, 30, 60, 90, and 120 for Cohorts 1-3.  Pharmacokinetic samples will be tested by MNA at pre -does 
and on Days 4, 30, 45, 60, 90, and 120 for cohort 4.  
The assessment of Cmax, 
Tmax, half -life (α and β), 
MRT, and AUC(0- t) for each of 
the monoclonal antibodies of G03-52-01 as measured by a 
validated electrochemiluminescence assay (ECLA) or valid ated 
enzyme -linked immunosorbent 
assay (ELISA).  
Pharmacokinetic samples will be tested by ECLA or ELISA at pre-dose, 2, 4, 8, 24, 48, and 72 
hours post injection, and on Details for addition of Cohort 4 
Protocol: G03-52-01.001 Version 3.0 
 September 7, 2021 
Ology Bioservices, Inc.  19 Proprietary  
 Days 4, 8, 15, 30, 45, 60, 90, 
and 120  
 
 
   Samples  will be tested to 
evaluate presence of anti -drug 
antibodies (ADA) collected for 
all cohorts. 
Samples will be tested for 
ADA at pre -dose, 15, 30, 45, 
60, 90, and 120  Days 4, 8, 15, 30, 45, 60, 90, 
and 120 for Cohorts 1- 3.   
Pharmacokinetic samples wil l 
be tested by ECLA or ELISA at pre-dose, 6 hours post-dose, 
and on Days 1, 2, 4, 8, 15, 30, 45, 60, 90, 120, and 180 for cohort 4.  
Samples will be tested to 
evaluate presence of anti -drug 
antibodies (ADA) collected for all cohorts. Samples will be tested  for ADA 
at pre-dose, 15, 30, 45, 60, 90, and 120 for cohorts 1-3.  
Samples will be tested for ADA at pre-dose and on Days 45, 60, 
90, 120, and 180 for Cohort 4.  
Page 29, Section 4 Study Design  
This is a first -in-human study 
consisting of three cohorts of 
ten subjects each.  Each subject will receive a single IM 
injection of G03-52-01 or 
placebo.   
 Section 4 Study Design 
This is a first -in-human study 
consisting of four cohorts of ten 
subjects each.  Each subject will receive a single  IM 
injection of G03-52-01 or placebo.   
 Additional cohort added.   
Page 29, Section 4 Study 
Design Table 1  
Cohort A, B, C Section 4 Study Design Table 1 
Cohort 1, 2, 3, and 4  Cohort 4 -  100mg, 10 subjects 
(8 active, 2 placebo) 
 Additional Cohort added with 
extended follow-up period. 
Page 30, Section 4 Study 
Design: Schedule for Subjects  
Subjects in all cohorts will participate in the study for Page 45, Section 4 Study 
Design: Schedule for Subjects  
Subjects in Cohorts 1- 3 will 
participate in the study for Additional Cohort added with extended follow-up period. 
 
Protocol: G03-52-01.001 Version 3.0 
 September 7, 2021 
Ology Bioservices, Inc.  20 Proprietary  
 approximately 150 days, 
including a 28- day screening 
period, a 12-hour inpatient stay 
and approximately 120- day 
follow-up after study product administration.  Subjects will remain at the clinic and not be 
eligible for discharge until 8 
hours after the IM injection.  Last follow up visit scheduled at Day 120.   
The end of the study is defined as the date of the last visit of the last subject in the study.  
 
      
 approximately 150 days, 
including a 28- day screen ing 
period, a 12-hour inpatient stay 
and approximately 120- day 
follow-up after study product administration.  Subjects will remain at the clinic and not be 
eligible for discharge until 8 
hours after the IM injection.  Last follow up visit scheduled at Day 120.   
Subjects in Cohort 4 will participate in the study for 
approximately 210 days, 
including a 28- day screening 
period, a 12-hour inpatient stay 
and approximately 180- day 
follow-up after study product 
administration.  Subjects will 
remain at the clinic and not be 
eligible for discharge until 8 
hours after the IM injection.  
Last follow up visit scheduled 
at Day 180.   
The end of the study is defined 
as the date of the last visit of 
the last subject in the study.   
 
         
Section 5.2 subject Exclusion 
Criteria  
 Section 5.2 subject Exclusion Criteria  
Addition of #24. Subjects with NX02 levels present at screening will be exclude from cohort 4.  
Page 34, Section 5.3.1 Randomization Procedures 
This is a Phase 1 double-blinded, placebo-controlled trial that will randomize 
subjects within three dosing Section 5.3.1 Randomization Procedures  
This is a Phase 1 double-
blinded, placebo-controlled trial that will randomize 
subjects within f our dosing  
Addition of cohort 4 
Protocol: G03-52-01.001 Version 3.0 
 September 7, 2021 
Ology Bioservices, Inc.  21 Proprietary  
 cohorts to either active or 
placebo in an overall 4:1 
ratio.    cohorts to either active or 
placebo in an overall 4:1 ratio.   
Section 6.2 Acquisition 
ICON Early Phase Services  
Attn: Jane Willman, RPh  
8307 Gault Lane 
San Antonio, TX 78209 Section 6.2 Acquisition  
ICON Early Phase Services  
Attn: Pharmacist 
8307 Gault Lane San Antonio, TX 78209 Jane Willman no longer at the site. 
Page 36, Section 6.3 Formulation. Packaging, and Labeling  
G03-52-01 will be 
administered intramuscularly (IM) as a single dose at 
concentrations of 10 mg, 25 mg, and 50 mg by varying the administration volume.  Page 52, Section 6.3 Formulation. Packaging, and Labeling  
G03-52-01 will be administered 
intramuscularly (IM) as a single 
dose at  concentrations of 10 
mg, 25 mg, 50 mg and 100 mg by varying the administration volume. Cohort 4 will receive 100mg dose.   
Page 40, Section 7.5.1.3 Pregnancy Testing  
A urine pregnancy test will be repeated on Day 4, Day 45, and Day 120 (end of study). Page 56, Section 7.5.1.3 
Pregnancy Testing  
A urine pregnancy test will be repeated on Day 4, Day 45, and end of study (Day 120 or Day 180, depending on cohort). Added cohort 4 with extended visit schedule 
Page 42, Section 7.6.2 Anti-Drug Antibody Assay  
Six-mL samples of blood will 
be drawn on Days 0, 15, 30,45,60, 90, and 120 for determining the presence of ADA using a validated ECLA that measures total anti- drug 
antibody in serum.   This will 
be done to assess 
immunogenicity.  Page 57, Section 7.6.2 Anti-Drug Antibody Assay 
Six-mL samples of blood will 
be drawn pre -dose on Day 0, 
and on Days 15, 30,45,60, 90, 
and 120 for determining the 
presence of ADA using a validated ECLA that measures 
total anti-drug antibody in 
serum for Cohorts 1-3.    
Six-mL samples of blood will 
be drawn pre-dose on Day 0 
and on Days 45, 60, 90, 120, Additional Cohort added with 
extended follow-up period. 
Protocol: G03-52-01.001 Version 3.0 
 September 7, 2021 
Ology Bioservices, Inc.  22 Proprietary  
 and 180 for determining the 
presence of ADA using a 
validated ECLA that measures total anti-drug antibody in 
serum for Cohort 4.  This will 
be done to assess immunogenicit y. 
 
Page 43, Table 2  
 Page 58, Table 2  
Updated to reflect additional 
visits on day 180 for Cohort 4. 
24hr/Day 1.  48hr/Day2 PK, MNA and ADA and 
Cumulative totals shown for Cohorts 1-3 and 4 separately  
Footnotes revised.  
 Additional Cohort added with extended follow-up period. 
Section 8.2 Visit 2: Baseline 
(Day0)   
• Obtain blood samples for 
Baseline serum PK (prior to 
injection and at the completion of the injection and 2hr, 4hr, and 8 hr post dosing) Section 8.2 Visit 2: Baseline (Day0)  
• Obtain blood samples 
for 
Baseline serum PK (prior to 
injection and at the completion of the 
injection and 2hr, 4hr, 
and 8hr post dosing for subjects in Cohorts 1-3. 
Baseline serum PK (prior to 
injection and at 6 hrs post-injection for subjects in Cohort 4) 
MNA (prior to injection for 
subjects in Cohorts 1-3) Added cohort 4 
Protocol: G03-52-01.001 Version 3.0 
 September 7, 2021 
Ology Bioservices, Inc.  23 Proprietary  
 MNA (prior to injection and at 
2 hours post injection for 
subjects in Cohort 4) 
ADA (prior to injection for all 
subjects)  
 
Section 8.3 visit 3: Out- patient 
Follow-up (24 hrs) 
• Obtain blood samples for the following: 
•   PK measurement  Section 8.3 vis it 3: Out- patient 
Follow-up (24 hrs/Day 1) 
• Obtain blood samples for the following: 
o PK measurement at 24 
hours for subjects in 
cohorts 1-3 
PK measurement at 24 hours 
(+/- 2houirs)  for subjects in 
cohort 4 Added cohort 4 
Section 8.4 Visit 4: Outpatient 
follow-up  Visit (48 hours) 
• Obtain blood samples for 
the following: 
•   PK measurement  Section 8.4 Visit 4: Outpatient 
follow-up  Visit (48 hours/Day 2) 
• Obtain blood samples for 
the following: 
o PK measurement at 48 
hours for subjects in 
cohorts 1-3 
o PK measurement 48 
hours (+/- 2 hours) for 
subjects in cohort 4 Added cohort 4 
Section 8.5 visit 5: Out- patient 
Follow-up (72 hours) Section 8.5 visit 5: Out- patient 
Follow-up (72 hours) Cohorts 
1-3 Specified visit for cohort 3 
Section 8.8 Visit 8: Out- patient 
Follow-up (Day 15 +1) 
• Obtain blood samples 
for the following: 
o Clinical Safety 
Labs  Section 8.8 Visit 8: Out- patient 
Follow-up (Day 15 +1) 
• Obtain blood samples for the following: 
o Clinical Safety 
Labs  Specified ADA for cohorts 1-3 
Protocol: G03-52-01.001 Version 3.0 
 September 7, 2021 
Ology Bioservices, Inc.  24 Proprietary  
 o PK 
measurement  
o ADA  
 o PK 
measurement  
o ADA (cohorts 1 -
3) 
 
Section 8.9 visit 9: Out- patient 
Follow-up (Day30 +1) 
• Obtain blood samples 
for the following: 
o Clinical Safety Labs  
o PK 
measurement  
o MNA 
o ADA  Section 8.9 visit 9: Out- patient 
Follow-up (Day30 +1) 
• Obtain blood samples 
for the following: 
o Clinical Safety Labs  
o PK 
measurement  
o MNA 
o ADA (cohorts 1 -
3) Specified ADA for cohorts 1-3 
Section 8.10  Visit 10: Out-
patient Follow -up (Day 45 +3) 
• Obtain blood samples 
for the following: 
o PK 
measurement  
o ADA  Section 8.10  Visit 10: Out-
patient Follow -up (Day 45 + 3)  
• Obtain blood samples 
for the following: 
o PK 
measurement  
o ADA  
o MNA (cohort 4)  Specified MNA for cohort 4  
Section 8.13 Visit 13: Final 
Visit/Early Termination Visit (Day 120 +3)  
• Obtain blood samples 
for the following: 
o Clinical Safety 
Labs  
o PK 
measurement  
o MNA 
o ADA  
 Section 8.13 Visit 13: Final 
Visit /Early Termination Visit for Cohorts 1-3 (Day 120 +3) / 
Cohorts 4 (Day 120 +3) 
• Obtain blood samples 
for the following: 
o Clinical Safety 
Labs (cohorts 1-
3) 
o PK 
measurement  
o MNA 
o ADA  
 Specified labs for cohorts 1-3 
Protocol: G03-52-01.001 Version 3.0 
 September 7, 2021 
Ology Bioservices, Inc.  25 Proprietary  
 Section 8.14 Section 8.14 Visit 14: Final 
Visit/Early Termination for subjects in Cohorts 4 (Day 180 +3)  
• Obtain vital signs  
• Review and update 
concomitant medications  
• Perform symptom directed PE  
• Obtain blood samples 
for the following: 
o Clinical Safety 
Labs  
o PK measurement  
o ADA  
• Obtain urine sample for dipstick analysis  
• Perform urine 
pregnancy test on 
women of child- bearing 
potential 
• Assessment of AEs and SAEs  
• Counsel women of 
child -bearing potential 
on the avoidance of 
pregnancy. Counsel the 
subject not to receive 
any botulinum toxin preparation (e.g.  
Botox) for 4 months 
after injection  Addition of Cohort 4 final visit  
Section 8.14 Unscheduled 
Visit  Section 8.15 Unscheduled Visit Section number update 
Section 9.3.2 Serious Adverse Events 
SAE Email Address: 
safety@ologybio.com Section 9.3.2 Serious Adverse Events  
SAE Email address: 
olo.safety@reilience.com  Revision to correct SAE email address  
Revision to correct Medical Monitor 
Protocol: G03-52-01.001 Version 3.0 
 September 7, 2021 
Ology Bioservices, Inc.  26 Proprietary  
 The DOD medical monitor and 
clinical project manager will 
be notified of the SAE by DOD PVG.   
The DOD medical monitor will review and assess the SAE for potential impact on study subject safety and protocol 
conduct.  The ICON medical monitor and 
clinical project manager will be notified of the SAE by DOD PVG.   
The ICON medical monitor will review and assess the SAE for potential impact on study subject saf ety and protocol 
conduct.  
Page xx, Section 9.6.3 DOD Medical Monitor 
The DOD Medical Monitor 
will communicate with the Ology Bioservices Medical Monitor for any safety related quest ions.  The DOD MM will 
participate in the planned SRC meetings and can make a recommendation that the SRC be convened to review any safety concerns.   Section 9.6.2 ICON Medical 
Monitor 
The ICON Medical Monitor 
will communicate with the Ology Bioservices  Medical 
Monitor for any safety related questions.  The ICON MM will participate in the planned SRC meetings and can make a recommendation that the SRC be convened to review any safety concerns.  Revision to correct section  
numbering and Medical Monitor 
Section 9.6.4 Ology 
Bioservices Medical Monitor  
The Ology Bioservices Medical Monitor will be the main point of contact for the ICON MM and the DOD MM, including any safety- related 
questions or concerns.  The Ology Bioservices MM will escalate any medical or  safety 
concerns to the DOD MM as needed.  Section 9.6.3 Ology Bioservices Medical Monitor  
The Ology Bioservices Medical Monitor will be the main point of contact for the ICON MM, including any safety- related 
questions or concerns.  The Ology Bioservices M M will 
escalate any medical or safety concerns to the DOD as needed.  Revision to correct section numbering and Medical Monitor 
Page xx, Section 9.6.5 Safety Review Committee (SRC)  
The SRC will be composed of:  
PI, or designee  
Ology Bioservices Medical 
Monitor  Section 9.6.4 Safety Review 
Committee (SRC)  
The SRC will be composed of:  
PI, or designee  
Ology Bioservices Medical 
Monitor  Revision to correct section 
numbering and name of Medical 
Monitor  
Protocol: G03-52-01.001 Version 3.0 
 September 7, 2021 
Ology Bioservices, Inc.  27 Proprietary  
 DOD Medical Monitor or 
designee;  
 
The SRC recommendation to 
advance to the next level will 
be documented and provided to all the appropriate parties 
(PI, Ology Bioservices and 
DOD) involved with the study. ICON Medical Monitor or 
designee;  
 
The SRC recommendation to 
advance to the next level will 
be documented and provided to all the appropriate parties (PI, 
Ology Bioservices, ICON, and 
DOD) involved with the study. 
Section 11.2 Planned Interim 
Analyses  
A blinded interim safety and PK analysis is planned for this study to analyze all PK, ADA, and MNA samples th rough 
Day 60. This will include all subject in all cohorts through Day 60. Stopping criteria are for safety and are defined in section 9.5. Section 11.2 Planned Interim Analyses  
A blinded interim safety and PK 
analysis is planned for this study 
to analyze all PK, ADA, and 
MNA samples for Cohorts 1 -3 
through Day 60.  A second 
blinded interim safety analysis is 
planned to analyze all PK, ADA, and MNA samples for Cohort 4 
through Day 90.  Stopping criteria 
are for safety and are defined in section 9.5.  
  
Appendix A: Schedule of 
Events Appendix A: Schedule of Events 
Addition columns added for 
Study Day 180 
Footnote s updated.   Additional Cohort added with extended follow-up period. 
  
Protocol: G03-52-01.001 Version 3.0 
 September 7, 2021 
Ology Bioservices, Inc.  28 Proprietary  
 SUMMARY OF CHANGES FOR VERSION 2.0 
 
Version 1.0  Version 2.0  Reason for Change  
Page 8:  List of 
Abbreviations Page 9:  List of Abbreviations  Added abbreviation for ELISA, 
HRPO, PVG, and PVSS  
Page 1 2: Protocol Summary, 
Study Outcome Measures: 
Secondary Endpoint:  The assessment of C
max, 
Tmax, half-life (α and β), MRT 
and AUC (0-t) for each of the 
monoclonal antibodies of 
G03-52-01 as measured by a 
validated electrochemiluminescence 
assay (ECLA) method.  
  
 Pharmacokinetic samples will be tested by ECLA at pre-dose, 2, 4, 8, 24, 48, and 
72 hours post injection, and on Days 4, 8, 15, 30, 45, 60, 90, and 120. 
 Page  17: Protocol Summary, 
Study Outcome Measures: 
Secondary Endpoint:  The assessment of C
max, Tmax, 
half-life (α and β), MRT and 
AUC (0-t) for each of the 
monoclonal antibodies of G03-
52-01 as measured by a validated 
electrochemiluminescence assay 
(ECLA) or an enzyme -linked 
immunosorbent assay (ELISA).  
  
 Pharmacokinetic samples will be tested by ECLA or ELISA at pre-dose, 2, 4, 8, 24, 48, and 72 
hours post injection, and on Days 4, 8, 15, 30, 45, 60, 90, and 120. 
 Added  enzyme -linked 
immunosorbent assay (ELISA) 
Page 1 2: Protocol Summary, 
Description of Study Design: 
PK samples will be tested by 
ECLA at pre -dose, 2, 4, 8, 
24, 48, and 72 hours  post 
dose and on days 4, 8, 15, 30, 45, 60, 90, and 120 for all cohorts.   Page  17: Protocol Summary, 
Description of Study Design: 
PK samples will be tested by 
ECLA or ELISA at pre -dose, 2, 
4, 8, 24, 48, and 72 hours  post 
dose and on days 4, 8, 15, 30, 45, 60, 90, and 120 for all cohorts.   
 Added ELISA  
Protocol: G03-52-01.001 Version 3.0 
 September 7, 2021 
Ology Bioservices, Inc.  29 Proprietary  
 Page 24: Section 4: Study 
Design Table 1 lists the IP as 
Dose of NTM -1634 Page 28: Section 4: Study Design Table 1 corrected name of IP to read Dose of G03-52-01 Revision to correct the name of 
the IP to G03-52-01 
Page 2 4: Section 3.2.2 
Secondary Endpoint:  
The assessment of C max, 
Tmax, half-life (α and β), MRT 
and AUC (0-t) for each of the 
monoclonal antibodies of 
G03-52-01 as measured by a 
validated electrochemiluminescence 
assay (ECLA) method.  
  
 Pharmacokinetic samples will be tested by ECLA at pre-dose, 2, 4, 8, 24, 48, and 
72 hours post injection, and on Days 4, 8, 15, 30, 45, 60, 90, and 120. Page 29 Section 3.2.2: Secondary Endpoint:  
The assessment of C
max, Tmax, 
half-life (α and β), MRT and 
AUC (0-t) for each of the 
monoclonal antibodies of G03-
52-01 as measured by a validated 
electrochemiluminescence assay 
(ECLA) or an enzyme -linked 
immunosorbent assay (ELISA).  
  
 Pharmacokinetic samples will be tested by ECLA or ELISA at pre-dose, 2, 4, 8, 24, 48, and 72 
hours post injection, and on Days 4, 8, 15, 30, 45, 60, 90, and 120. 
 Added  ELISA  
Page 3 6: Section 7.6.1 
Pharmacokinetic Assay  
Serum will be analyzed for 
levels of each of the 
antibodies using a validated 
ECLA.  Five-mL samples of blood will be drawn to be 
analyzed for neutralizing 
antibody concentrated using the validated Batte lle MNA.  
 Page 41: Section 7.6.1 
Pharmacokinetic Assay  
Six-mL of blood will be drawn 
for the analysis of levels of each 
of the monoclonal antibodies in 
serum using a validated ECLA or ELISA.  Ten -mL samples of 
blood will be drawn to be analyzed for neutral izing 
antibody concentrated using the validated Battelle MNA.  Added ELISA and revised the 
amount of blood to be drawn for 
analysis.  
Page 3 7 Section 7.6.2 Anti-
Drug Antibody Assay  
Six-mL samples of blood 
will be drawn on Days 0, 15, 
30,45,60, 90, and 120 for 
determining the presence of Page 42 Section 7.6.2 Anti -Drug 
Antibody Assay 
Six-mL samples of blood will be 
drawn on Days 0, 15, 30,45,60, 90, and 120 for determining the 
presence of ADA using a Added that ECLA assay is 
validated  
Protocol: G03-52-01.001 Version 3.0 
 September 7, 2021 
Ology Bioservices, Inc.  30 Proprietary  
 ADA using an ECLA assay 
that measures total anti- drug 
antibody in serum.   This 
will be done to assess immunogenicity.  
 validated ECLA that measures 
total anti-drug antibody in serum.   This will be done to assess immunogenicity.  
 
Page 38 Table 2: Laboratory 
Samples and Estimated Total Blood Volume (mL) Page 43 Table 2: Laboratory 
Samples and Estimated Total Blood Volume (mL) Estimated blood volume  
Page 40 Section 8.2 Visit 2/Baseline  Page 45 Section 8.2 Visit 2/ Baseline:  Added MNA  Added MNA  
Page 42 Section 8.6 Visit 6/Day 4  Page 47 Section 8.6 Visit 6/Day 4:  Added MNA Added MNA  
Page 42 Section 8.8 Visit 8/Day 15 Page 47 Section 8.8 Visit 8/Day 15: Added: 
Counsel women of child- bearing 
potential on the avoidance of 
pregnancy  
Counsel the subject not to 
receive any botulinum toxin 
preparation (e.g.  Botox) for 4 months after injection  Added: 
Counsel women of child- bearing 
potential on the avoidance of 
pregnancy  
Counsel the subject not to receive any botulinum toxin preparation (e.g.  Botox) for 4 months after injection  
Page 43 Section 8.9 Visit 
9/Day 30 Page 48 Section 8.9 Visit 9/Day 30:  Added MNA Added MNA  
Page 43 Section 8.11 Visit 11/Day 60 Page 49 Section 8.11 Visit 11/Day 60:  Adde d MNA  Added MNA  
Page 44 Section 8.12 Visit 12/Day 90 Page 49 Section 8.12 Visit 12/Day 90:  Added MNA Added MNA  
Page 44 Section 8.13 Visit 13/Day 120 Page 49 Section 8.13 Visit 13/Day 120:  Added MNA Added MNA  
Protocol: G03-52-01.001 Version 3.0 
 September 7, 2021 
Ology Bioservices, Inc.  31 Proprietary  
  
  
  Page 47 Section 9.3.2 
Serious Adverse Events:  ICON Medical Monitor  
SAE Phone: 443-983-1332 Page 53 Section 9.3.2 Serious 
Adverse Events:  ICON Medical Monitor 
SAE Phone: 410-294-2537 Revision in Medical Monitor 
Phone Number to Report SAE. 
 
Revision captured in Administrative Letter to Protocol dated March 5, 2020 
N/A Page 56 Section 9.6.2 ICON Medical Monitor Added the ICON Medical 
Monitor and defined the role 
N/A Page 56 Section 9.6.3 DOD Medical Monitor Added the DOD Medical 
Monitor and defined the role 
N/A Page 56 Section 9.6.4 Ology Bio Medical Monitor Added the Ology Bio Medical 
Monitor and defined the role 
Page 63 Appendix A: 
Schedule of Events Page 69: Appendix A: Schedule of Events Added MNA as a line item on 
the Schedule of Events 
Protocol: G03-52-01.001 Version 3.0 
 September 7, 2021 
Ology Bioservices, Inc.  32 Proprietary  
 PROTOCOL SUMMARY  
Title:   
A Phase 1, Randomized, Double-Blind, Dose Escalation Study to Evaluate the 
Safety and Pharmacokinetics of a Single IM Dose of G03-52-01 vs Placebo in Adult Subjects. 
 
 
Phase:  
 1 
 
Population: 
 40 healthy male and female subjects between 18 -45 years of age  
 
Number of Sites:  
 One 
 
Study Duration: 
 Approximately 10 months. 
 
Subject Participation Duration 
 Subjects in  Cohorts 1-3 will participate approximately 150 days (up to 28-day 
screening , 12-hour inpatient stay, up to 120 days  outpatient follow -up) 
Subjects in Cohort 4 will participate approximately 210 days (up to a 28- day 
screening, up to 12-hour clinic stay, up to 180-day outpatient follow-up) 
Description of Agent:   
G03-52-01 drug product is a mixture of five human monoclonal IgG 1 antibodies 
(NX01, NX11, XB10, XB18, and XB23) and one humanized monoclonal IgG 1 
antibody (NX02) which bind to non-overlapping epitopes on BoNT/ A/B.   
  
  
Protocol: G03-52-01.001 Version 3.0 
 September 7, 2021 
Ology Bioservices, Inc.  33 Proprietary  
 Study 
Objectives:  Primary Objective:   
 
• To assess the safety and tolerability of escalating doses of G03 -52-01 
administered intramuscularly ( IM) in healthy adult subjects  
 
Secondary Objective:  
 
• To assess the pharmacokinetics  (PK) and immunogenicity of escalating 
doses of G03-52- 01 administered IM in healthy adult subjects  
 
Study Outcome Measures:  
 Primary Endpoints :   
 
• The occurrence of Serious Adverse Events  (SAE) following 
administration of G03-52-01 to the final follow-up visit.  
• The occurrence of Adverse Events (AE) from administration of G03-52-
01 to the final follow-up visit. 
 
• The occurrence of changes from baseline in physical examination, vital signs and clinical safety laboratory values following administration of G03-52-01 to the final follow-up visit.  
 
Secondary Endpoints:  
• The pharmacokinetic assessment of C
max, Tmax and AUC (0-t) as measured 
by the validated Battelle Mouse Neutralization Assay (MNA) for serotypes A and B.  
 
o Pharmacokinetic samples will be tested b y MNA at p re-dose and 
on Days 4, 30, 60, 90, and 120 for Cohorts 1-3.  
o Pharmacokinetic samples will be tested by MNA at pre -dose, 2-
hour post-dose (for future use), and on Days 4, 30, 45, 60, 90, and 120 for Cohort 4.  
 
The assessment of C
max, Tmax, half-life (α and β), MRT and AUC (0-t) for 
each of the monoclonal antibodies of G03-52-01 as measured by a 
validated electrochemiluminescence assay  (ECL A) or an enzyme-linked 
immunosorbent assay (ELISA).  
o Pharmacokinetic samples will be tested by ECL A or ELISA  at 
pre-dose, 2, 4, 8, 24, 48, and 72 hours post injection, and on 
Days 4, 8, 15, 30, 45, 60, 90, and 120 for Cohorts 1-3. 
o Pharmacokinetic samples will be tested by ECLA or ELISA at pre-dose, 6 hours post dose, and on Days 1, 2, 4, 8, 15, 30, 45, 
60, 90, 120, and 180 for Cohort 4. 
 
Protocol: G03-52-01.001 Version 3.0 
 September 7, 2021 
Ology Bioservices, Inc.  34 Proprietary  
 • Samples collected to evaluate presence of anti -drug antibodies (ADA)  
collected for all cohorts.  
 
o Samples will be tested for ADA at pre -dose and on Days 15, 30, 
45, 60, 90, and 120 for Cohorts 1-3. 
o Samples will be tested for ADA at pre -dose and on Days 45, 60, 
90, 120, and 180 for Cohort 4. 
 
 
Estimated Time 
to Complete Enrollment:  
 Appr oximately 5 months. 
Description of Study Design:  A Phase 1, randomized, double -blind, placebo -controlled dose escalation trial of 
four dose cohorts outlined below:  
• Cohort 1: 10 mg IM injection (8 active, 2 placebo) 
• Cohort 2: 25 mg IM injection (8 active, 2 placebo) 
• Cohort 3: 50 mg IM injection (8 active, 2 placebo) 
• Cohort 4: 100mg IM injection (8 active, 2 placebo) 
 
Dosing for each cohort is as follows: Two sentinel subjects will be administered 
a single IM dose (one G03 -52-01, one placebo).  The dosing of the remain ing 
eight  subjects within that cohort will not be initiated until at least 24 hours have 
passed and no adverse events have occurred that meet halting criteria, and no safety signals have occurred that in the opinion of the investigator warrant further investigation.   The remaining eight subjects in the cohort will be admitted as scheduled without delay. Dose escalation will not occur until safety data through Day 8 is reviewed by the Safety Review Committee  (SRC)  
composed of the P rincipal Investigator (PI) , Ology Bi oservices  Medical 
Monitor, and the ICON  Medical Monitor . Objective dose- escalation  criteria and 
safety evaluations will be utilized. A SRC meeting will be held at any time during the course of the study if halting criteria are met or safety concerns arise.  
The study will consist of a twenty -eight -day screening period and up to 12-hour 
clinic st ay.  Follow-up visits will occur  at 24 hours, 48 hours, and 72 hours post 
dose and on Days 4, 8, 15, 30, 45, 60, 90, and 120 for Cohorts 1-3.  Follow-up visits for subjects in Cohort 4 will occur at on Days 1, 2, 4, 8, 15, 30, 45, 60, 90, 120, and 180. 
Subjects will be screened for Human Immunodeficiency Virus ( HIV), Hepatitis 
B surface antigen ( HBsAg ), and antibody to Hepatitis C virus ( HCV), drugs and 
alcohol.  Safety parameters include physical examination, 12 -lead 
Electrocardiogram ( ECG ), vital sig ns, and clinical laboratory values to include: 
Protocol: G03-52-01.001 Version 3.0 
 September 7, 2021 
Ology Bioservices, Inc.  35 Proprietary  
 Complete Blood Count ( CBC ) with differential, comprehensive metabolic 
panel, and urine dipstick for protein, blood, an d glucose with reflex microscopy .   
Cohorts 1-3: Pharmacokinetic ( PK) samples will be drawn at pre-dose, 2, 4, 8, 
24, 48, and 72 hours post dose and on days 4, 8, 15, 30, 45, 60, 90, and 120.  PK 
samples will be tested by  the Battelle Mouse Neutralization Assay (MNA) for 
serotypes A and B at pre -dose and on days 4, 30, 60, 90, and 120.  PK samples 
will be tested by ECL A or ELISA  at pre-dose, 2, 4, 8, 24, 48, and 72 hours  post 
dose and on days 4, 8, 15, 30, 45, 60, 90, and 120.  S amples will be tested for 
anti-drug antibodies (ADA) at pre-dose and days 15, 30, 45, 60, 90, and 120.   
Cohort 4:  PK samples will be tested by the Battelle Mouse Neutralization Assay (MNA) for serotypes A and B at pre-dose , 2-hours post-dose ( future use ) 
and on days 4, 30, 45, 60, 90, and 120.  PK samples will be tested by ECLA or ELISA at pre -dose, 6 hours post-dose, and on days 1, 2, 4, 8, 15, 30, 45, 60, 90, 
120, and 180.  Samples will be tested for anti-drug antibodies (ADA) at pre-dose and days 45, 60, 90, 120, and 180. 
A Safety Review Committee ( SRC) meeting will be held if halting criteria are 
met or safety concerns arise.     
 
    
Protocol: G03-52-01.001 Version 3.0 
 September 7, 2021 
Ology Bioservices, Inc.  36 Proprietary  
 Schematic of Study Design  
 
Assess  Eligibility 
Randomize  
  
Cohort 1 N=10  
Single IM injection of 10mg G03 -52-01  
(8 subjects) or Placebo (2 subjects)  
 
Dose -Escalation Halting Criteria Not Met  
SRC Agrees to Dose Escalation  
 
Cohort 2 N=10  
Single IM injection of 25mg G03-52 -01 
 (8 subjects) or Placebo (2 subjects)  
 
Dose -Escalation Halting Criteria Not Met  
SRC Agrees to Dose Escalation  
 Study Halting Criteria Met/Dose Escalation 
Halting Criteria Met/SRC Review  
Study Halting Criteria Met/Dose -Escalation 
Halting Criteria Met/SRC Review  
Safe to Proceed  
 Halt Study  
Safe to Proceed  
 Halt Study  
Dose -Escalation Halting Criteria Not Met  
SRC Agrees to Dose Escalation  
Study Halting Criteria Met/Dose -Escalation 
Halting Criteria Met/SRC Review  
Safe to Proceed  
Halt Study  
 Cohort 3 N=10  
Single IM injection of 50mg G03-52 -01  
(8 subjects) or Placebo (2 subjects)  
 
Cohort 4 N=10  
Single IM injection of 100 mg G03- 52-01  
(8 subjects) or Placebo (2 subjects)  
 
SRC Review Assessment of Final Outcome 
Measures  
Protocol: G03-52-01.001 Version 3.0 
 September 7, 2021 
Ology Bioservices, Inc.  37 Proprietary  
 1.  KEY ROLES 
Principal Investigator:  
Cassandra Key, MD  
Sr. Medical Director, ICON Early Phase Services  
8307 Gault Lane 
San Antonio, TX 78209 Telephone: 210-283-4572 
Email: cassandra.key@iconplc.com   
Ology Bioservices Medical 
Monitor:  
 
   
John A bernethy, MD 
Ology Bioservices, Inc.  
13200 NW Nano Court 
Alachua, FL 32615 Telephone:  352-213-5757 Email:  john.abernethy@resilience.com
  
 
 
CRO Safety and 
Pharmacovigilance Contractor: 
  ICON Pharmacovigilance & Safety Services  
Unit 2, Globeside Business Park  
Marlow  
SL7 1HZ 
United Kingdom PV email:  ICON -Safety -CentralReceipt@iconplc.com
  
 
Protocol: G03-52-01.001 Version 3.0 
 September 7, 2021 
Ology Bioservices, Inc.  38 Proprietary  
 Central Laboratory for Safety 
Testing:  
 
  Back up Laboratory for Safety 
Testing:  
 
 Research Labo ratory for PK and 
ADA Samples:  ICON Early Phase Services LLC.  
8307 Gault Lane San Antonio, TX 78209  Quest Diagnostic Clinical Laboratories Inc.  
4770 Regent Blvd. Irving, TX 75063  Ology Bioservices, Inc.  
2601 Challenger Drive, Suite 101 Alameda, CA 94501 
Research Laboratory for MNA  
Samples:                                                                                                                Battelle  
1425 State Route 142  
West Jefferson, OH 43162  
Protocol: G03-52-01.001 Version 3.0 
 September 7, 2021 
Ology Bioservices, Inc.  39 Proprietary  
 2. BACKGROUND INFORMATION AND SCIENTIFIC 
RATIONALE  
2.1. Background Information  
2.1.1.   Introduction 
Botulism is caused by absorption of Botulinum Neurotoxin ( BoNT ) into the blood stream 
following oral ingestion (food-borne botulism), through the growth of C. botulinum  in the 
gastrointestinal tract (infant botulism), in wounds contaminated by the organism (wound 
botulism), or through inhalation (inhalation botulism).1 There are 7 BoNT serotypes (A -G)2 
which differ by 35-68% at the amino acid level.  Recent data has been published identifying a 
BoNT/H serotype that appears to b e a hybrid of A and F serotype.3 Three of the BoNT serotypes 
(A, B, E) cause up to 99% of the cases of human botulism .4,5 
Botulism is characterized by prolonged paralysis, which is either immediately fatal or requires prolonged hospitalization in an Intensive Care Unit and mechanical ventilation.  The onset and 
severity of symptoms depends on the amount of toxin absorbed.  Onset of symptoms typically occurs 12-72 hours after ingestion, with a range of up to 8 days.  Recovery from the paralysis 
does not occur until new nerve growth occurs. Mechanical ventilator support is commonly 
needed for 2 to 8 weeks, with some patients requiring support for up to 7 months.
6, 7 
The development of approaches to treat or prevent biothreat botulism has been designated a high 
priority area by the National Institu te of Allergy and Infectious Diseases (NIAID) [see NIAID 
Biodefense Research Agenda for the Centers for Disease Control  and Prevention ( CDC ) 
Category A Agents].8  In June 2011, the Federal Experts Advisory Panel (FESAP) published 
recommendations concerning the Select Agent Program to address the requirements of Executive 
Order 13546, “ Optimizing the Security of Biological Select Agents and Toxins in the United 
States ”, published in the Federal Register on July 8th, 2010; the recommendations of the FESAP 
classified Botulinum toxins as “Tier 1” agents.   
2.1.2.   Currently Available Treatments  
Equine antitoxin and human botulism immune globulin are currently used to treat adult 9, 10 and 
infant botulism, 11 respectively.  Traditional antitoxins are not readily renewable resources, 
requiring animal or human immunization, plasmapheresis or bleeding, and serum processing for each lot.  Moreover, each lot produced will vary in antibody composition, potency, dosi ng, and 
possibly safety profile. Human botulism immune globulin is produced by plasmapheresing 
laboratory personnel who have been immunized because they are at risk of exposure to BoNT.
11  
Although human botulism immune globulin has been shown to be both safe and effective for 
treating infant botulism, scaling of this product for the biothreat drug repository is not feasible.11  
Moreover, the pentavalent toxoid used to produce botulism immune globulin is no longer available,
12 raising questions concerning the ability to continue to make this product. 
With the  previous generation of equine antitoxin  there was a 9% incidence of acute or  delayed 
hypersensitivity reactions, including serum sickness (3.7%) and anaphylactic shock (1.9%).9 The 
observed side effects are attributable to the residual content of the equine Fc region.  The current generati on heptavalent equine antitoxin (HBAT) also is produced from horses, but is more 
Protocol: G03-52-01.001 Version 3.0 
 September 7, 2021 
Ology Bioservices, Inc.  40 Proprietary  
 thoroughly digested to yield largely Fab and Fab’ 2 to theoretically reduce the incidence of 
hypersensitivity reactions.13  HBAT has a  very short serum half -life (8 -34 hours depending on 
serotype) and as a result, an approximately 2% incidence of recurrence of botulism occurs after 
treatment, a phenomenon called BoNT reintoxication.14  HBAT has an approximately 1% 
incidence of anaphylaxis, as reported at the 2011 Interagency Botulism Coordinating Committee Meeting by CDC.  Rapid deployment of equine antitoxin also is complicated by the inability to use it prophylactically and the need to dilute the product 10-fold and infuse intravenously (IV) 
slowly over hours.  Finally, the potency of equine antitoxins, such as HBAT, can vary 
significantly for sub -serotypes where there is significant sequence difference between the 
immunizing sub -serotype and other sub-serotypes .  
2.1.3.   G03 -52-01 Development  
G03-52-01 drug product is being investigated for the treatment of botulinum neurotoxin and 
prophylaxis of inhalation botulism from serotypes A and B in adults.  G03 -52-01 is a mixture of 
five human IgG1 antibodies and one humanized IgG1 antibody each with distinct specificities 
that are individually expressed in a Chinese hamster ovary (CHO) cell line. Each of the drug substance antibodies (anti-BoNT/A NX01, NX02, NX11 and anti-BoNT/B XB10, XB18, XB23) used in the manufacture of G03-52-01 binds non-overlapping regions on BoNT/A or BoNT/B. 
While each of the mAbs binds to a distinct epitope on BoNT/A or BoNT/B, none was able to 
sufficiently neutralize BoNT when tested alone in vivo . The in vivo  studies showed that the 
highest levels of mAb potency were dependent on the presence of three antibodies.
15 The 
protective capacity of G03 -52-01 to neutralize toxicity caused by BoNT/A and BoNT/B has been 
verified in mice and  in guinea pigs. 
As these drug products are directed at foreign targets not expressed in animals or humans and 
based on the observed lack of cross- reactivity of G03-52-01 in healthy human and animal tissue, 
the focus of the nonclinical safety evaluation of G03-52-01 was to assess potential off -target 
toxicity and to identify any untoward effects due to administration of either drug product.   
A GLP 12- week repeat dose toxicity study was performed to evaluate the safety  of G03 -52-01 in 
rate when administered by intramuscular injection once weekly for three injections and to 
evaluate toxicity  and reversibility of effects after a two -month recovery period.  The study 
consisted of four Main Study/Recovery dose groups (15 rats/sex/group) and four Toxicokinetic (TK) dose groups (12 rats/sex/group) Experimental endpoints included moribundity/mortality; physical examinations, injection site (Draize) reactogenicity scoring; body weigh ts; food 
consumption; body temperature measurements; clinical pathology parameters (clinical chemistry, hematology, and coagulation); serum drug levels/toxicokinetics; organ weights; gross pathology at necropsy; and microscopic pathology. IM treatment at d oses of 10, 50, or 100 
mg/kg of G03 -52-01 against botulinum neurotoxins A and B did not result in any treatment-
related, toxicologically significant, or adverse findings following three injections on Study Days 1, 8, and 15. Therefore, the No Observed Adve rse Effect Level (NOAEL) was 100 mg/kg for this 
study.  
Protocol: G03-52-01.001 Version 3.0 
 September 7, 2021 
Ology Bioservices, Inc.  41 Proprietary  
 2.1.4.   Public Readiness and Emergency Preparedness Act  
This protocol and the study product tested are covered under the Public Readiness and 
Emergency Preparedness (PREP) act.  The PREP Act provides compens ation to participants in 
the event of serious physical injury or death caused by covered drugs and vaccines, and liability 
protection for persons conducting the clinical trial and the manufacturer of the drug or vaccine. 
On October 10, 2008, an amendment was issued to the Declaration for use of the PREP act to 
include countermeasures to treat, identify, or prevent adverse health consequences or death from 
exposure to botulinum toxin. (Federal Register, Volume 73 , Number 202, Pages: 61864-61866).  
The study product used in this clinical trial is one such countermeasure.  The PREP act provides immunity for covered persons (such as Manufacturers, Distributers, Program planners and other qualified persons who prescribe, administer or dispense the study product) from tort liability, 
unless the injury was caused by willful misconduct. 
The PREP Act also authorized a “Covered Countermeasures Process Fund” to provide compensation to eligible individuals who suffer specified injuries from administration or use of a 
countermeasure pursuant to the declaration.  Any requests for compensation must be filed within 
one year of administration or use of the countermeasure.  Requests would go to the HRSA 
Preparedness Countermeasures Injury Compensation Program (http://www.hrsa. gov/cicp).  
Compensation may then be available for medical benefits, lost wages and death benefits to eligible individuals for specified injuries in accordance with regulations published by the Secretary.  Eligibility for compensation and the injuries for which compensation may be available are further defined by regulation. 
An individual who suffers a serious physical injury or death from the admin istration and use of 
the study product must first seek compensation from the Covered Countermeasures Process 
Fund.  A serious physical injury means an injury that is life threatening, results in, or requires 
medical or surgical intervention to prevent, permanent impairment of a body function or permanent damage to body structure.  Any compensation will be reduced by public or private insurance or worker’s compensation available to the injured individual. 
If no funds have been appropriated to the compensation program, the Secretary does not make a 
final determination on the individual’s request within 240 days, or if the individual decides not to 
accept the compensation, the injured individual or his representative may pursue a tort claim in 
the US  District Court for the District of Columbia, but only if the claim involves willful 
misconduct, is pled with particularity required under the PREP Act, verified, and accompanied 
by an affidavit by a physician who did not treat the individual and certified medical records.  
Any award is reduced by any public or private insurance or worker’s compensation available to the inju red individual.  Awards for non-economic damages, such as pain, suffering, physical 
impairment, mental anguish, and loss of consortium are also limited.  If the individual accepts compensation, or if there is no willful misconduct, the individual does not have a tort claim that  
can be filed in a US  Federal or a State court.  
Protocol: G03-52-01.001 Version 3.0 
 September 7, 2021 
Ology Bioservices, Inc.  42 Proprietary  
 2.2. Rationale  For Use of G03-52-01  
Based on nonclinical and clinical experience with other anti -BoNT mAbs, use of G03 -52-01 for 
the treatment of botulism and prophylaxis of inhalation botulism from serotypes A and B in 
adults may provide the following advantages over the equine antitoxins:   
• An improved safety profile  
 Subs tantially decreased anaphylaxis and no risk of serum sickness  
 G03-52-01 is  directed at  foreign targets not expressed in animals or humans 
 Toxicity studies demonstrated a lack of cross- reactivity of G03-52-01 in  
healthy human tissue  
 A similar product targeting BoNT  serotype A  was well tolerated and no 
safety concerns were observed  in a Phase 1 clinical study  
 A similar product targeting BoNT serotype B was well tolerated and no safety concerns were observed in a Phase 1 clinical trial  
• A longer half- life 
• The ability to administer repeated doses for prevention and therapy 
• The ability to use small doses via IV and IM administration (permitting flexible administration scenarios, including self -administration)  
• The ability to easily and consistently manufacture a large number of doses in sufficient quantities for sto ckpiling 
The proposed starting dose for G03-52-01 dose escalation (10 mg IM) is based on previous toxicology and clinical studies of anti-BoNT mAbs that included intravenous dosing. The 10 mg IM dose includes 5 mg of anti-BoNT/A mAbs (NX01, NX02, and NX11; similar to NTM -1631, 
formerly XOMA 3AB) and 5 mg of anti-BoNT/B mAbs (XB10, XB18 and XB23; similar to NTM -1632, formerly XOMA 3B). 
NTM -1631 and NTM-1632 have undergone Phase 1 clinical testing under protocols very similar 
to Protocol G03-52-001.001. These studies were placebo -controlled, double-blind, dose 
escalation studies to evaluate the safety and tolerability of each drug. Each subject received a single intravenous (IV) infusions of study drug or placebo administered over one hour, as an 
inpatient, at one of three dose levels (0.33, 0.165, or 0.033 mg/kg) equating to approximately 25, 
12, or 2.5 mg assuming a 75 kg subject. All three doses of each drug were safe and generally well tolerated during and following infusion. No pattern of treatment emergent adverse events 
was seen at any of the doses. None of the three NTM -1631 mAbs induced an antibody response 
or augmentation of preexisting antibodies in the few subjects who had them and similar analysis 
of NTM -1632 antibody response is underway. 
Doses wil l escalate to 25 mg and then to 50 mg up to 100mg provided there are no safety 
concerns. The nonclinical IND-enabling toxicology studies were designed to support this clinical design with intramuscular route of administration.  Based on data received from the Day 60 
blinded interim safety and PK analysis, it was determined to escalate to 100mg single dose.  
Protocol: G03-52-01.001 Version 3.0 
 September 7, 2021 
Ology Bioservices, Inc.  43 Proprietary  
 2.3. Potential Risks and Benefits  
2.3.1.   Potential Risks  
The potential risks to the subjects due to participation in the study are those related to 
venipuncture, the IM injection and the administration of G03 -52-01 
Venipuncture 
Venipuncture causes transient discomfort and may cause fainting.  Bruising at the site of the 
venipuncture may occur but can be prevented or lessened by applying pressure for several 
minutes. Infection at the site is possible but highly unlikely as aseptic technique must be employed.  
IM Injection  
An IM injection may cause some discomfort at the injection site.  Other risks may include pain, redness, swelling, or wa rmth at the injection site.  These risks are minimal.  
G03-52-01 
As G03 -52-01 has not been administered to humans, the potential risks are based on adverse 
events associated with NTM -1631and NTM -1632 in the Phase 1 studies , infusion or injection of 
other antibody products, in particular other monoclonal antibody preparations against non-human targets, and the possibility of allergic reactions, especially IgE -mediated and serum sickness -like 
reactions . 
Adverse Events with a Similar Product 
A summary of all Adverse Events ( AEs) asses sed as related on the NTM -1631 clinical protocol 
following administration of NTM -1631 follows: 
NTM -1631 dose level 0.033mg/kg:  
• One female subject experienced a moderate decrease in hemoglobin reported 1- week  post 
infusion.  She also had a mild elevation in Alanine Aminotransferase ( ALT ) 2 weeks post 
infusion. 
• One male subject experienced moderate protein in the urine one- week  post infusion and a 
mild elevation in Aspartate Aminotransferase ( AST ) two months post infusion. 
• One male subject experienced a moderate elevation in blood sugar three days post infusion and then again two weeks post infusion. 
NTM -1631 dose level 0.165mg/kg: 
• One female subject experienced a mild increase in neutrophils starting one-month post infusion. 
NTM -1631 dose level 0.330mg/kg: 
• No associated AEs were reported in subjects receiving NTM -1631 at this dose. 
No safety signals or trends were identified on this protocol and a placebo subject also had a mild increase in AST and ALT three day s post infusion.   
Protocol: G03-52-01.001 Version 3.0 
 September 7, 2021 
Ology Bioservices, Inc.  44 Proprietary  
 A summary of all AEs assessed as related with the NTM -1632 clinical protocol following 
administration of NTM -1632 is as follows: 
NTM -1632 dose level 0.033mg/kg:  
• One female subject experienced mild throbbing pressure on forehead during infusion  
• One female subject experienced mild lightheadedness during infusion  
NTM -1632 dose level 0.33mg/kg 
• One female subject experienced mild loose stools 1-day post infusion 
Risk Factors Associated with Monoclonal Antibodies 
Injections of mAbs may be ass ociated with injection reactions including : 
anaphylaxis/anaphylactoid type reaction, especially during a first exposure, and when 
administered rapidly.  Fever, chills and rigors, typically occurring within the first two hours 
following injection , character ize these reactions.  Other symptoms sometimes associated with 
injection reactions include nausea, vomiting, rash, pruritus, bronchospasm or other acute 
pulmonary response, angioedema, hypotension, hypertension, cardiac arrhythmias, dizziness, dyspnea, hea dache, and malaise.  
Risk of Immunogenicity 
Antibodies directed against G03 -52-01 may develop following injection .  This will be assessed 
by taking blood samples at selected visits throughout the study.  G03 -52-01 is a fully humanized 
mAb which based on experience with other humanized or chimeric mAbs, reduces the immunogenic potential.   
2.3.2. Known Potential Benefits  
This trial has no benefit for the subjects participating in the trial.  The knowledge gained in this trial may help society, especially those exposed to, or at risk of being exposed to, the toxins of botulism.  
3. OBJECTIVES 
3.1. Study Objectives  
Primary Objective:   
• To assess the safety and tolerability of escalating doses of G03 -52-01 administered IM  in 
healthy adult  subjects.  
Secondary Objective:  
• To assess the ( PK) and immunogenicity of escalating doses of G03-52- 01 administered 
IM in healthy adult subjects . 
Protocol: G03-52-01.001 Version 3.0 
 September 7, 2021 
Ology Bioservices, Inc.  45 Proprietary  
 3.2. Study Outcome Measures  
3.2.1. Primary Endpoints  
• The occurrence of Serious Adverse Events following administration of G03-52-01 to  the 
final follow -up visit. 
• The occurrence of Adverse Events from administration of G03 -52-01 to the final follow-
up visit. 
• The occurrence of changes from baseline in physical examination, vital signs and clinical 
safety laboratory values following adm inistration of G03 -52-01 to  the final follow -up 
visit. 
3.2.2. Secondary Endpoint s 
• The pharmacokinetic assessment of C max, Tmax and AUC (0-t) as measured by the validated 
Battelle Mouse Neutralization Assay (MNA) for serotypes A and B  
o Pharmacokinetic samples will be tested by MNA at pre -dose and on Days 4, 30, 
60, 90, and 120 for Cohorts 1 -3. 
o Pharmacokinetic samples will be tested by MNA at pre -dose, 2-hours post-dose 
(future use), and on Days 4, 30, 45, 60, 90, and 120 for Cohort 4. 
• The assessment of C max, Tmax, half-life (α and β), MRT,  and AUC (0-t) for each of the 
monoclonal antibodies of G03-52-01 as measured by a validated 
electrochemiluminescence assay (ECL A) or validated enzyme-linked immunosorbent 
assay (ELISA) . 
o Pharmacokinetic samples will be tested by ECL A or ELISA  at pre-dose, 2, 4, 8, 
24, 48, and 72 hours post injection, and on Days 4, 8, 15, 30, 45, 60, 90, and 120 
for Cohorts 1-3.  
o Pharmacokinetic samples will be tested by ECLA or ELISA at pre -dose, 6 hours 
post-dose, and on Days 1, 2, 4, 8, 15, 30, 45, 60, 90, 120, and 180 for Cohort 4. 
• Samples will be tested to evaluate presence of anti -drug antibodies  (ADA) collected for 
all cohorts. 
o Samples will be tested for ADA at pre -dose, 15, 30, 45, 60, 90, and 120 for 
Cohorts 1-3. 
o Samples will be tested for ADA at pre -dose and on Days 45, 60, 90, 120, and 180 
for Cohort 4. 
4. STUDY DESIGN 
This is a Phase 1, single- center, placebo -controlled, double-blind, dose- escalation study to 
evaluate the safety and tolerability of G03-52-01 in healthy adults. This is a first- in-human study 
consisting of four Cohorts of ten  subjects each.  Each subject will receive a single IM injection  of 
G03-52-01 or placebo .   
Protocol: G03-52-01.001 Version 3.0 
 September 7, 2021 
Ology Bioservices, Inc.  46 Proprietary  
  
Table 1:  Cohorts 
Cohort  Dose of G03-52-01  Number of Subjects  
1 10 mg 10 subjects ( 8 active, 2 placebo)  
2 25 mg 10 subjects ( 8 active, 2 placebo)  
3 50 mg 10 subjects ( 8 active, 2 placebo)  
4 100 mg  10 subjects (8 active, 2 placebo)  
 
Schedule for S ubjects  
Subjects in Cohorts 1-3 will participate in the study for approximately 150 days , including a 28-
day screening period, up to12-hour inpatient stay and approximately 120- day follow- up after 
study product administration.  Subjects will remain at the clinic and not be eligible for discharge 
until 8 hours after the IM injection .  Last follow up visit scheduled at Day 120.   
Subjects in Cohort 4 will participate in the study for approximately 210 days, including a 28- day 
screening period, up to a 12-hour clinic stay and approximately 180-day follow-up after study product administration.  Subjects will remain at the clinic and not be eligible for discharge until approximately 8 hours after the IM injection.  Last follow up visit scheduled at Day 180.   
The end of the study is defined as the date of the last visit of the last subject in the study. 
Schedule for Cohorts 
Since this is a first -in-human study, administration of the study products to subjects in a cohort 
will occur over a period of up to two weeks to allow careful observation of individuals for 
adverse events.  Two sentinel subjects within each cohort will be admitted initially  and will be 
administered a single IM injection , and the randomization scheme will be designed to ensure that 
one subject will receive G03-52-01 and the other will receive p lacebo.  The dosing of the 
remaining eight subjects within that cohort will not be initiated until at least 24  hours have 
passed and no adverse events have occurred that meet halting criteria, and no safety signals have occurred that in the opinion of the investigator warrant further investigation.   The remaining eight subjects in the cohort will be admitted  as scheduled without delay.   An alternate subject 
will be admitted to the unit for each two -subject group. Up to four alternates per cohort will be 
recruited.  Dose escalation will not occur until safety data through Day 8 is  reviewed by the 
Safety Review Committee (SRC) composed of the Principal Investigator (PI), Ology Bioservices Medical Monitor, and the ICON  Medical Monitor. 
 
4.1 Study Enrollment and Withdrawal  
Only subjects who meet all of  the inclusion and none of the exclusion criteria will be eligible 
for enrollment into this study.   No exemptions are granted on Inclusion/Exclusion Criteria in 
DOD-sponsored studies. 
Protocol: G03-52-01.001 Version 3.0 
 September 7, 2021 
Ology Bioservices, Inc.  47 Proprietary  
 Forty  healthy male and female subjects, ages 18 to 45 years old, will be enrolled in four cohorts.  
Up to four alternates per cohort will be recruited.   Alternates who meet all eligibility criteria 
may effectively have their check -in at the same time as the lead two subjects and be rolled over 
into the next group within that cohort but will not be dosed until 24 hours after the initial two 
subjects are dosed  (Cohorts 1 -3).  Alternates not enrolled into a dosing group within a cohort 
are eligible for enrollment into the next group for that cohort. Alternates not enrolled into the 
cohort are eligible for enrollment in subsequent cohorts but would have to undergo re- screening  
with the exception of the viral serology labs listed in section  7.5.1.1 if more than 28 days have 
passed  since collection of screening laboratory parameters . 
4.1.1 Subject Inclusion Criteria  
All must be answered yes for the subject to be eligible for study participation  
1. Informed consent understood and signed 
2. Healthy male or healthy, non -pregnant, non- lactating female  
3. Willingness to comply and be available for all protocol procedures   
4. Between 18 and 45 years of age on the day of IM injection 
5. Body Mass Index (BMI) of ≥18.5 and ≤ 35 kg/m2  
6. If the subject is female and of childbearing potential, she has  a negative serum  pregnancy 
test at screening and negative urine test within 24 hours prior to IM injection  
• Note: A woman is considered of childbearing potential unless post- menopausal (≥ 
1 year without menses) or surgically sterilized via bilateral oophorectomy, or hysterectomy or bilateral tubal ligation or successful Essure placement with documented confirmation test at least 3 months after the procedure. 
7. If the subject is female and of childbearing potential, she agrees to practice abstinence from sexual intercourse with men or use acceptable contraception  during participation in the 
study  
• Note: Acceptable contraception methods are restricted to effective devices (Intrauterine Contraceptive Devices)  
8. The hemoglobin, platelet count, white blood cell count and absolute neutrophi l count are not 
below the LLN and ≤ULN x 10%  
• Abnormalities in mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC), red cell distribution width (RDW), mean platelet volume (MPV), and nucleated red blood 
cell count (NRBC CT), which are included in a complete blood count with 
differential, will not be exclusions.  
 
9. The urine dipstick results on protein, glucose and blood are negative or trace  
 
• Note: Menstruating females failing inclusion criteria due to a positive blood on urine dipstick may be retested following cessation of menses.   
Protocol: G03-52-01.001 Version 3.0 
 September 7, 2021 
Ology Bioservices, Inc.  48 Proprietary  
 • Note: When a urine dipstick is more than trace positive for blood (whether a 
menstruating female or other subjects), that subject would not be excluded if the 
urine microscopic exam shows <5 rbcs/hpf. 
 
10. Chemistry screening lab oratory tests as  outlined in Section 7.5.1.4 are in the normal 
reference range  
• Note: The following exceptions to laboratory normal reference ranges are 
allowed: Creatinine, Blood Urea Nitrogen (BUN), total bilirubin, AST, ALT, lipase, amylase, Prothrombin Time (PT), Partial Thromboplastin Time (PTT) below the lower limit of normal (L LN); CK less than 400U/L ; Glucose, 
potassium, total protein, and alkaline phosphatase with a toxicity grade of 1 is allowable ; albumin above the upper limit of normal (ULN).  
• Laboratory values that are outside the range of eligibility but are thought to be due to an acute condition or due to laboratory error may be repeated once. 
11. The urine drug screen is negative  
12. Breathalyzer test is negative 
13. Available for follow-up for the duration of the study  
14. Agrees not to participate in vigorous activity 72 hours prior to dosing through day 15 post dosing 
4.1.2 Subject Exclusion Cr iteria  
Subjects meeting  any of the following exclusion criteria are not eligible for participation . 
All must be answered no for the subject to be eligible for study participation 
1. History of a chronic medical condition that would either interfere with the accurate assessment of the objectives of the study or increase the risk profile of the subject. 
• Note: Chronic medical conditions include but not limited to diabetes; Asthma requiring use of medication in the year before screening; Autoimmune disorder 
such as lupus, Wegener’s, rheumatoid arthritis, thyroid disease; Coronary artery 
disease; Chronic hypertension; History of malignancy except low-grade (squamous and basal cell) skin cancer thought to be cured; chronic renal, 
hepatic, pulmonary, or endocrine disease (except previous asthma which has 
required no treatment for the past year);  
2. History of severe allergic reaction of any typ e to medications, bee stings, food, or 
environmental factors or h ypersensitivity or reaction to immunoglobulins.   
• Note: Severe allergic reaction is defined as any of the following: anaphylaxis, 
urticaria, or angioedema 
3. A marked baseline prolongation of QT/QTc interval (e.g., repeated demonstration of a 
QTc interval >450 milliseconds) 
4. Clinically significant abnormal electrocardiogram at screening .  
Protocol: G03-52-01.001 Version 3.0 
 September 7, 2021 
Ology Bioservices, Inc.  49 Proprietary  
 • Note: Clinically significant abnormal ECG results include  but not limited to : 
complete left or right bundle branch block; other ventricular conduction block; 
2nd degree or 3rd degree atrioventricular (AV) block; sustained ventricular 
arrhythmia; sustained atrial arrhythmia; two Premature Ventricular Contractions in a row; pattern of ST elevation felt consistent with cardiac ischemia; or any condition deemed clinically significant by a study investigator 
5. Positive serology results for HIV, HBsAg, or HCV antibodies  
6. Febrile illness with temperature ≥ 38°C within 7 days of dosing 
 
7. Pregnant or breastfeeding  
 
8. Donated blood within 56 days of enrollment  
9. Known allergic reactions to any of the study product components present in the formulation or in the processing, as listed in the Investigator Brochure   
10. Treatment with another investigational drug within 28 days of dosing  
11. Treatment with  a monoclonal antibody within 3 months of enrollment.   
 
12. Receipt of antibody (e.g. TIG, VZIG, IVIG, IM gamma globulin) or blood transfusion within 6 months or within 5 half-lives of the specific product given 
 
13. Active drug or alcohol use or dependence that, in the opinion of the investigator, would 
interfere with adherence to study requirements 
 
14. Use of H1 antihistamines or beta-blockers within 5 days of dosing 
 
15. Use of any prohibited medication within 28 days prior to study entry or planned use during 
the study period  
• Note: Prohibited medications include immunosuppressives (except Nonsteroidal Anti-Inflammatory Drugs [NSAIDS]); immune modulators; oral corticosteroids 
(topical/intranasal steroids are acceptable); anti-neoplastic agent s; any vaccine 
(licensed or investigational) . Subjects will be eligible to receive any authorized 
COVID -19 vaccine after they complete Study Day 8 
16. Previous exposure to botulinum toxin, receipt of antibodies against botulinum toxin, or previous treatment with equine antitoxin  
 
17. Any previous injection or planned injection within 4 months after enrollment of botulinum toxin for cosmetic reasons, spastic dysphonia, torticollis, or any other reason 
 
Protocol: G03-52-01.001 Version 3.0 
 September 7, 2021 
Ology Bioservices, Inc.  50 Proprietary  
 18. Any specific condition that in the judgment of the investigator precludes participation 
because it could affect subject safety  
 
19. Plans to enroll or is already enrolled in another clinical trial* that could interfere with 
safety assessment of the investigational product at any time during the study period  
 
• Note: Includes trials that have a study intervention such as a drug, biologic, 
or device  
 
20. Is a study site employee or staff  
• Note: Site employees or staff include the PIs and sub- investigators or staff 
who are supervised by the PI or Sub-Investigators  
21.  Systolic blood pressure >140mm Hg or diastolic blood pressure >90 mm Hg 
a.   Grade 1 values may be repeated once if the PI believes a transient condition let to the aberrant value and are allowable unless deemed clinically significant by 
the PI.  
 
22. Resting hea rt rate <50 or >100 beats per minute 
 
23. Oral temperature ≥ 38°C (100.4°F)  
 
24.  Subjects with NX02 antibody levels present at screening will be excluded from Cohort 4. 
4.2 Treatment Assignment Procedures  
4.2.1 Randomization Procedures  
Randomized treatment assignments will be generated by a statistician at ICON PLC .  
Randomization will occur following admittance to the unit and confirmation of eligibility is 
confirmed. 
This is a Phase 1 double-blinded, placebo -controlled trial that will randomize subjects within 
four dosing Cohorts to either active or placebo  in an overall 4:1 ratio.   For each dosing cohort, 
the first two subjects will be randomized in a 1 :1 fashion to active and placebo to ensure that one 
of the first two subjects receiv es active treatment and the other control.   An alternate subject will 
be admitted to the unit for each two-subject group.  If one of the first two subjects is not 
randomized for any reason, then the alternate subject will receive the next consecutive 
randomization number. The product assignment of the remaining eight subjects in each cohort 
will be a simple random sample to ensure the 4:1 ratio for the dosing cohort.  The randomization list will be generated by the unblinded study biostatistician and transferred to the unblinded study pharmacist prior to start of the study.    
If 2 or more subjects withdraw, are lost to follow up or terminate prior to Day 8, those subjects need to be replaced to ensure that data for at least 7 subjects is available for review . 
Protocol: G03-52-01.001 Version 3.0 
 September 7, 2021 
Ology Bioservices, Inc.  51 Proprietary  
 If 2 or more subjects withdraw, are lost to follow up or terminate prior to Day 60 or are not 
compliant with all PK draws through Day 15, they may be replaced.   
If more than 2 subjects withdraw, are lost to follow up or terminate following the Day 8 SRC 
review of safety data, the site will attempt to replace those subjects in that dose group at the time of the next planned cohort. 
4.2.2 Masking Procedures  
The study staff participating in the administration of study product and assessment of the 
subjects will not be aware of the contents of the IM vial .  The G03 -52-01 and placebo will look 
identical,  so the study staff and the subject will not be able to determine whether placebo or G03 -
52-001 is being i njected . 
The Investigator may unblind a subject’s treatment assignment only in the case on an emergency 
or SAE, when knowledge of the study treatment is essential to the appropriate clinical 
management or welf are of the subject.  Whenever possible, the Investigator should first discuss 
the options with the Ology Bioservices Medical Monitor or appropriately designated Ology 
Bioservices personnel before unblinding the subject’s treatment assignment.  If this is 
impractical, the Investigator must notify Ology Bioservices as soon as possible but without revealing the subject’s treatment assignment.  The date and reason for unblinding must be recorded on the SAE form.  
4.2.3 Reasons for Withdrawal 
A subject may withd raw from the study at any time for any reason, without any consequence.  
A study subject will be discontinued from participation in the study if any of the following 
reasons occur prior to dosing: 
• Development of any exclusion criteria;  
• Request by the subj ect to terminate participation;  
• Requirement for prohibited concomitant medication or treatment; 
A subject may be removed from the study for the following reasons post dosing; however, whenever possible the subject should be followed for safety per protocol: 
• Failure to adhere to the p rotocol requirements  
• Lost to follow-up; 
• Request of primary care provider; 
• At the request of the Institutional Review Board ( IRB)/Ethics committee , Food and 
Drug Adm inistration (FDA), or DOD; 
• The subject’s well -being  based on the opinion of the investigator;  
• The occurrence of a Serious Adverse Event (SAE) or (AE warranting withdrawal ). 
Protocol: G03-52-01.001 Version 3.0 
 September 7, 2021 
Ology Bioservices, Inc.  52 Proprietary  
 4.2.4 Handling of Withdrawals  
Subjects who are withdrawn prior to dosing may be replaced. Following dosing, one subject per 
cohort may withdraw prior to the completion of Visit 11 (D ay 60)  or was noncompliant with all 
PK draws through Visit 6  (Day 4)  without being replaced.  Should more than one subject from the 
same cohort voluntarily withdraw  from the study who did not meet the above criteria, those 
subject s may be replaced.  Subjects who withdraw or are withdrawn from the study who received 
any amount of the study product will be encouraged to continue follow -up (with subjects’ consent) 
for safety.   Subjects withdrawing will be asked to complet e a final termination visit if they do not 
wish to be followed per protocol. 
4.2.5 Lost to Follow- up 
In the case of subjects who fail to appear for a follow-up assessment, extensive effort (i.e., three 
documented contact attempts via phone calls, e- mail, etc., made on separate occasions and 
followed by a certified letter) will be made to locate or recall them, or at least to determine their health status.  These efforts will be documented in the subjects’ records. 
4.2.6 Termination of Study  
Although the study Sponsor has every intention of completing the study, it reserves the right to 
terminate the study at any time for clinical or administrative reasons.  
5. STUDY PRODUCT S 
5.1. Description of Study Products  
G03-52-01 drug product is a mixture of five human monoclonal IgG 1 antibodies and one 
humanized monoclonal IgG 1 antibody, which bind to  non-overlapping epitopes on BoNT/ A/B.  
Each of the component antibodies, NX01, NX02, NX11, XB10, XB18, and XB23, is separately 
produced in CHO cell lines.  Each mAb comprising G03 -52-01 has distinct human variable 
regions that bind to BoNT/A/B.  No subtypes of BoNT/A or BoNT/B have been described.  
Placebo is 0.9% Sodium Chloride Injection, USP is a sterile, nonpyrogenic, isotonic solution of sodium chloride and water for injection.   
5.2. Acquisition  
The G03 -52-01 will be supplied by Ology Bioservices, Inc . Study product will be shipped to the 
following address:  
 
ICON Early Phase Services  
Attn:  Pharmacist  
8307 Gault Lane 
San Antonio, TX 78209 
Protocol: G03-52-01.001 Version 3.0 
 September 7, 2021 
Ology Bioservices, Inc.  53 Proprietary  
  
The normal saline for injection will be supplied by ICON.  
5.3. Formulation, Packaging, and Labeling  
G03-52-01 
G03-52-01 is a mixture of five human IgG1 antibodies and one humanized IgG1 antibod y 
lyophilized in a single use vial to 55 mg per vial.  When reconstituted with water for injection 
(WFI), the drug product is a clear, colorless, sterile aqueous solution in a pH 6 buffered vehicle without preservatives.   
Cohorts 1-3: The drug product will be supplied in 2- mL, pyrogen -free, Type 1 glass vials fitted 
with Teflon -coated butyl rubber stoppers and flip-up aluminum seals.   
Cohort 4: The drug product is supplied in a 3mL/13mm glass serum/lyophiliz ed vial fitted with a 
13-mm FluroTec
™-coated stopper and flip- up aluminum seal.  
G03-52-01 will be administered intramuscularly (IM) as a single dose at concentrations of 10 
mg, 25 mg, 50 mg, and 100 mg by varying the administration volume.  
 
Placebo (Normal Saline, 0.9% Sodium Chloride, USP)  
0.9% Sodium Chloride Injection, USP is a sterile, nonpyrogenic, isotonic solution of sodium 
chloride and water for injection.  Each mL contains sodium chloride 9 mg and contains no 
preservatives, bacteriostatic, antimicrobial agent, or added  buffer.  The solution is clear in 
appearance with a pH range of 4.5 to 7.0.    
5.4. Product Storage and Stability  
G03-52-01 
G03-52-01 drug product will be shipped refrigerated at 2-8°C (36-46°F) and should be stored 
refrigerated at 2 -8°C (36- 46°F) until time o f preparation.  If a vial is removed from refrigeration 
it must be used within 8 hours.  If not used, it must be quarantined and maintained for study 
product accountability as per Section 6.6. G03 -52-01 should be protected from direct sunlight. 
G03-52-01 is not light sensitive under normal shipping and storage conditions.  The product 
should be used within 30 minutes upon reconstitution.  Avoid vigorous shaking or agitation. 
 
Placebo (Normal Saline, 0.9% Sodium Chloride, USP) 
Store at 20ºC to 25ºC (68°F to 77ºF) [See USP Controlled Room Temperature; excursions 
between 15°C and 30°C (59°F and 86°F) are permitted].  Protect from freezing.  
5.5. Dosage, Preparation and Administration  
The unblinded site Research Pharmacist will prepare the study drug on the same day as administration.  Prior to using any of the parenteral products, inspect for discoloration or 
Protocol: G03-52-01.001 Version 3.0 
 September 7, 2021 
Ology Bioservices, Inc.  54 Proprietary  
 particulate matter before use.  Any product that fails inspection should be quarantined at 2-8°C 
for inspection by the Sponsor. Preparation of the product will be performed using aseptic 
technique under a sterile environment (e.g., Biologic Safety Cabinet or laminar flow hood). Based on the subject assigned cohort randomization, the appropriate G03 -52-01 dose will be 
calculated,  and the appropriate number of vials will be removed from storage to prepare the 
injection.   Vials containing  G03 -52-01 should not be vigorously shaken. Water for injection  will 
be used to reconstitute the G03 -52-01 for IM  injection .  Any unused portion le ft in the vial 
should be retained for study product accountability as per Section 6.6. The placebo will be a normal saline  injection  without the addition of G03 -52-01.  The product should be used within 
30 minutes upon reconstitution. 
The subjects will be admitted to the Phase 1 unit the day of t he planned injection .  Verification 
that the subject still meets all inclusion criteria and does not have any exclusion criteria must be 
made prior to randomization. The unblinded site Research P harmacist will prepare the injection 
as described and t he injection  must be completed within 30 minutes after preparation.  G03-52-
01 or Placebo should be administered as a single I M injection  to the central, thickest portion of 
the deltoid .   
5.6. Accountability Procedures f or the Study Products  
The Site Principal Investigator is responsible for the distribution and disposition of study product (both G03-52-01 and placebo) and has ultimate responsibility for accountability.  The site Principal Investigator may delegate this r esponsibility to the unblinded site Research Pharmacist.  
If delegated, the site Research Pharmacist will be responsible for maintaining complete records and documentation of study product receipt, accountability, dispensation, temperature monitoring, and storage conditions, and final disposition of the study product.   
All study products, whether administered or not, must be documented on the appropriate study 
product accountability record or dispensing log. Used and unused G03 -52-01 vials and placebo 
vials will be retained until monitored and released for disposition as per r equirements.       
Upon completion of the study and after the final monitoring visit, any remaining unused study product will either be returned or destroyed appropriately at the clini cal site as per sponsor 
requirements and instructions, or in accordance with disposition plans. 
5.7. Assessment of Subject Compliance with Study Product  
Because each dose of G03 -52-01 will be administered by site personnel, subject compliance is 
not anticipate d to be an issue. 
5.8. Concomitant Medications  
Concomitant medication information will be recorded at Screening for the prior 28 days.  At each subsequent study visit each new concomitant medication and changes to existing  
medications will be recorded.   Subjec ts will be required not to utilize non -study medication or 
herbal supplements during the study except those deemed necessary by the site PI or sub investigator .  Any drug (e.g., over- the-counter herbal supplement, vita mins or prescription) used 
Protocol: G03-52-01.001 Version 3.0 
 September 7, 2021 
Ology Bioservices, Inc.  55 Proprietary  
 by the subject during the course of the trial will be recorded in the subject’s source documents 
and on the appropriate eCRF. 
Subjects will be instructed to refrain from the receipt of any of the following during study 
participation unless medically indicated and deemed immediately necessary by their private 
physician : 
• Blood or blood products, 
• Any antibody (e.g. TIG, VZIG, IVIG, IM gamma globulin)  
• Any vaccines (licensed or investigational)  
*Subjects will be eligible to receive any authorized COVID- 19 vaccine after they 
complete Study Day 8 
• Monoclonal antibody 
• Botulinum toxin 
• H1 antihistamines  
• Beta-blockers 
• Immunosuppressives (except NSAIDS)  
• Immune modulators 
• Oral corticosteroids (topical/intranasal  steroids are acceptable)  
• Anti-neoplastic agents  
6. STUDY PROCEDURES  
6.1. Medical History  
Medical history will be obtained by direct interview.  Subjects will be queried regarding a history of significant medical disorders of the head, eyes, ears, nose, throat (HEENT), mouth, cardiovascular system, lungs, gastrointestinal tract, liver, pancreas, kidney, urologic, nervous 
system, blood, lymph glands, endocrine system, musculoskeletal system, skin, and 
genital/reproductive tract.  A history of any allergies, cancer, immunodeficiency, psychiatric illness, substance abuse, and autoimmune disease will be solicited. The medical history will 
include current and past medical diagnoses, hospitalizations and major surgical procedures. 
Demographic information (date of birth, gender, race, ethnicity) will be obtained as part of the medical history assessment.   The medical history will be obtained at screening and updated upon 
admittance to the unit on Day 0.  
6.2. Physical Examination  
An abbreviated physical examination ( PE) will be conducted at the screening visit and Day 0.  
Height and weight will be obtained at s creening .  An abbreviated PE  is distinguished from a 
complete PE  as all body system assessments are not required (e.g., pelvic, rectal, etc.).  On Da y 
Protocol: G03-52-01.001 Version 3.0 
 September 7, 2021 
Ology Bioservices, Inc.  56 Proprietary  
 0, the PE will focus assessment  for the presence of the following in order to detect sign s of a 
hypersensitivity reaction :  
o General appearance including alertness and any difficulty breathing.   
o  HEENT (confirm no swelling of lips/tongue/uvula)  
o Chest (confirm no stridor or wheezing)  
o Heart (assess regularity of rhythm)  
o Skin (confirm no hives, examine for any eruptions)  
o Joints (confirm no swelling, warmth, or tenderness) 
A symptom- directed PE  will be performed at all other in -clinic  study visits.  Refer to the  MOP 
for further details.   Any new findings on examination post dosing or worsening of existing 
conditions are to be reported as AEs .   
6.3. Vital Signs 
Vital sign assessments including systolic and diastolic blood pressure ( BP) [ measured after 
sitting for at least  10 minutes ], heart rate (HR),  and oral temperature will be performed at each 
in-clinic study visit.   Vital signs that are thought to be aberrant due to an error in measurement 
may be repeated. Dur ing screening and follow -up, a measurement that is a Grade 1 (as 
referenced in Appendix B Toxicity Grading) may be repeated once if the PI believes a transient 
condition led to the aberrant value.   
Vital signs obtained at screening  will serve as baseline values for the subject.  Grade 1 values are 
allowable unless deemed clinically significant by the study investigator. 
6.4. Electrocardiogram  
A 12 -lead ECG will be performed at screening and reviewed by the study PI or a co -Investigator 
to assess the cardiac status of a subject for eligibility for enrollment. ECGs will be performed 
after the subject rests quietly in a supine position for at least 10 minutes. To be eligible for participation, the QT interval should be ≤ 450ms, and there must be no clinically significant ECG 
abnormalities according to the study in vestigators  and may be repeated once.     
6.5. Laboratory Evaluations  
Venipuncture schedule and volumes are displayed in Table 2.  
6.5.1.  Screening Laboratory Tests  
6.5.1.1. Viral Serology Testing 
Subjects will be screened for HIV, HBsAg, and antibody to HCV.  These tests must be negative 
for eligibility into the study. In cases where a false positive result is suspected, confirmatory 
testing may be performed (e.g., Polymerase Chain Reaction ).   
 
Protocol: G03-52-01.001 Version 3.0 
 September 7, 2021 
Ology Bioservices, Inc.  57 Proprietary  
    7.5.1.2       Drug Screen  
A urine toxicology screen will be performed to detect for the presence of the following: cocaine 
(and metabolite ), barbit urates, benzodiazepines, opiates, THC, metha mphetamine/amphetamine , 
methadone and PCP. The results must be negative for eligibility into the study.   A br eathalyzer 
test will also be performed  and results must be negative for eligibility into the study . 
 
 7.5.1.3 Pregnancy Testing  
For women of child-bearing potential, a serum pregnancy test will be done at screening and must 
be negative.  A urin e pregnan cy test will be done at Visit 2  (Day  0), which must be reported as 
negative before dosing. A urine pregnancy test will be repeated on Day 4 , Day 45, and end of 
study (Day 1 20 or Day 180 (Cohort 4 only).  
  
7.5.1.4 Screening Laboratory Tests  
• Hematology: hemoglobin, WBC with differential, absolute neutrophil count and platelet 
count. MCV, MCH, MCHC, RDW, MPV, which are included in a complete blood count 
with differential, will not be graded. 
• Chemistry:  serum creatinine, BUN, calcium, total bilirubin, dire ct bilirubin, indirect 
bilirubin, alkaline phosphatase, PT, PTT, INR, ALT, AST, sodium, potassium, and total CK.  
• Urinalysis: dipstick: Urine protein, blood and glucose must be negative or trace. 
Menstruating females failing with a positive blood on urine dipstick may be retested 
following cessation of menses.  If dipstick is abnormal, a complete urinalysis with 
microscopic will be performed.  When a urine dipstick is more than trace positive for 
blood (whether a menstruating female or other subject), that subject would not be 
excluded if the urine microscopic exam shows <5 RBC/HPF.  
Laboratory values that are outside the range of eligibility but are thought to be due to an acute 
condition or due to laboratory error may be repeated once.   Laboratory values will be entered in 
the Clinical Labs eCRF . 
6.5.2.  Safety Laboratory Tests 
The following laboratory tests will be done at screening and end of study.  Subjects should be 
fasting.  This means no food or drink (other than water) for at least eight hours prior to sampling. 
Safety labs with a Grade 1 value (Appendix B) will not exclude a subject from participation but 
will serve as their baseline value.   
• Hematology: hemoglobin, WBC with differential, absolute neutrophil count and platelet count. MCV, MCH, MCHC, RDW, MPV, which are included in a complete blood count with differential, will not be graded . 
Protocol: G03-52-01.001 Version 3.0 
 September 7, 2021 
Ology Bioservices, Inc.  58 Proprietary  
 • Chemistry:  serum creatinine, BUN, calcium, total bilirubin, direct bilirubin, indirect 
bilirubin, alkaline phosphatase, PT, PTT, INR , ALT, AST, sodium, potassium, and total 
CK.  
• Urinalysis: dipstick: Ur ine protein, blood and glucose must be negative or trace. 
Menstruating females failing with a positive blood on urine dipstick may be retested 
following cessation of menses. 
6.5.3. Hypersensitivity Panel  
A hypersensitivity panel include s cytokine and complement panels, IgE and tryptase. This 14 mL 
sample will be drawn on Day 0 prior to dosing. The sample will be processed only if the subject 
has a hypersensitivity reaction. If a subject develops anaphylaxis or anaphylactoid reaction, an 
additional 14 mL sample will be drawn during the event and another will be drawn after the event.  Refer to the Manual of Procedures for further details.  
6.6. Special Assays or Procedures  
6.6.1.   Pharmacokinetic Assay  
Six-mL of blood will be drawn for the analysis of  levels of each of the monoclonal antibodies in 
serum  using a validated  ECL A or ELISA .  Three t en-mL samples of blood will be drawn to be 
analyzed for neutralizing antibody concentrated using the validated Battelle MNA .  
6.6.2.  Anti -Drug  Antibody Assay 
Six-mL samples of blood will be drawn pre-dose on Day 0, and on Days 15, 30, 45, 60, 90, and 
120 for determining the presence of ADA using a validated ECLA  that measures total anti- drug 
antibody in serum for Cohorts 1 -3.   This will be done to assess immunogenicity.  
Six-mL samples of blood will be drawn pre-dose on Day 0 and on Days 45, 60, 90, 120, and 180 
for determining the presence of ADA using a validated ECLA that measures total anti -drug 
antibody in serum for Cohort 4.  This will be done to assess immunogenicity.  
6.6.3.  Future Use  
Five-mL samples of blood will be drawn for subjects who consent to have samples stored for 
future use.  These sampl es will be collected at Day  0, 8 and 30 for all cohorts and 2 hours post 
dose for cohort 4. 
This blood sample may be used in new or different laboratory tests, to provide information for 
the development of new drug products, or for the studies of botulism or other infections. 
6.6.4. Specimen Preparation, Handling, and Shipping  
Details regarding the spec imen preparation, handling, storage, and shipping are descr ibed in the 
MOP.  
 
Protocol: G03-52-01.001 Version 3.0 
 September 7, 2021 
Ology Bioservices, Inc.  59 Proprietary  
 Table 2:  Laboratory Samples and Estimated Total Blood Volume (mL)   
 
Study Visit  
 01 02 03 04 05 06 07 08 09 10 11 12 13 14 Total  
Cohorts 
1-3 Total 
for 
Cohort 
4 
Day -28 
to 
 -3 Baseline  24  hr  
 48 hr/  
 72 hr  
 4 
 8 
±1 15 
±1 30 
±1 45 
±3 60 
±3 90 
±3 120 
±3 180 
±3   
Dosing   X               
HIV, HBV,HCV 
Serum β -HCG  
4               
4  
4 
 
Screening Labs   
9  
              
9  
9 
 
Safety Labs    
9      
9  
9  
9     
9e  
9  
45  
45 
PKa  (cohorts 1 -3)  
  
24a 
  
     6  
6  
6  
6  
6  
6  
6  
6  
6 
  
6 
  
6  
6  
90  
 
PKa  (cohorts 4)   12 6 6  6 6 6 6 6 6 6 6 6  78 
MNA (cohorts 1 -3)  30    30   30  30 30 30  180  
MNA (cohorts 4)   30    30   30 30 30 30 30   210 
ADA (cohorts 1-3)    
6       
6  
6  
6  
6  
6  
6  
  
42  
 
ADA (cohorts 4)   6        6 6 6 6 6  36 
Future Usec   
5     
  
5   
5       
15  
15 
Hypersensitivity 
panel   
  
14b  
       
   
  
    
14  
14 
Total Volume/  
Visit (cohorts 1 -3)  
13  
88  
6  
6  
6  
36  
20  
21  
56  
12  
42  
42  
51  
51  
399e  
 
Total Volume/  
Visit (cohort 4)   
13  
76  
6  
6  
  
36  
20  
15  
50  
42  
42  
   42  
42  
27   
417 
Cumulative Totald 
Cohorts 1-3  
13  
101  
107 
  
113  
119  
155  
175  
196  
252  
264  
306  
348  
399e 
  
   
Protocol: G03-52-01.001 Version 3.0 
 September 7, 2021 
Ology Bioservices, Inc.  60 Proprietary  
 Cumulative Total  
Cohorts 4   
13  
89  
95  
101  
101  
137  
157  
172  
222  
264  
306  
   348  
390  
417   
 
a PK serum  samples taken  prior to injection and 2hr, 4hr, 8hr, 24hr, 48hr, 72hr post -dose, and on days 4, 8, 15, 30, 45, 60, 90, and 120 for cohorts 1- 3;  PK serum samples taken prior to 
injection and 6 -hr post -dose, and on days 1, 2, 4, 8, 15, 30, 45 , 60, 90, 120 and 180 for Cohort 4.  
b If a subject develops anaphylaxis or anaphylactoid reaction, an additional 14ml will be drawn during the event and after the event.   In this instance an additional 28 ml may be 
drawn from a subject than is reflected in the table totals.  
c For subjects consenting to future use  
d Total estimated volume drawn will vary slightly depending on future use consent and need for additional draws for the occurrence of hypersen sitivity  
e Subjects in Cohorts 1- 3 only  
 
Protocol: G03-52-01.001 Version 3.0 
 September 7, 2021 
Ology Bioservices, Inc.  61 Proprietary  
 7. STUDY SCHEDULE  
The Schedule of Events is included as Appendix A. 
7.1. Visit 1: Screening (Day -28 to Day -3) 
After providing written informed consent, each subject will be assigned a Subject ID number and 
undergo an eligibility assessment.  The following will be done during the screening period 
(within 28 days prior to administration of study product).  Results of screening tests and 
procedures will be evaluated by the investigator to determine eligibility prior to enrollment and randomization.  The following procedures will be performed. 
• Record demographics including age, gender, race and ethnicity .  Obtain contact 
information. 
• Obtain medical history.  The medical history will include the following:  
 current medical diagnoses 
 past medical diagnoses  
 hospitalizations  
 major surgical procedures   
 blood transfusions or immunoglobulin within the last 6 months 
 live vaccines within the last 28 days  
 killed vaccines within th e last  28 days  
 *Subjects will be eligible to receive any authorized COVID -19 vaccine after they 
complete Study Day 8 
 
 blood donation within the last 56 days 
 allergic reactions  
 drug and/or alcohol use or dependence 
 receipt of investigational drug within the last 28 days  
 Receipt of monoclonal antibody in the past  
 Exposure to botulinum toxin in the past 4 months 
• Review concomitant m edication history, including all medications  taken within the 
last 28 days  
• Review current use of contraceptive methods and recent menstrual history (female 
subjects only) 
Protocol: G03-52-01.001 Version 3.0 
 September 7, 2021 
Ology Bioservices, Inc.  62 Proprietary  
 • Perform abbreviated PE by licensed clinician listed on the Form FDA 1572 [ examples  
include Medical Doctor, Nurse Practitioner  and Physic ian’s Assistant ] 
• Obtain height and weight and calculate BMI  
• Take vital signs (systolic and diastolic blood pressure, pulse rate,  and oral 
temperature)  
• Obtain fasting blood samples for viral serology, clinical  laboratory screening tests  
• Obtain blood sample for serum pregnancy test for women of child bearing potential 
• Obtain blood to assess NX02 antibody levels (Cohort 4 subjects only) 
• Obtain urine sample for dipstick urinalysis and urine toxicology 
• Obtain 12- lead ECG  
• Perform Breathalyzer  test for recent alcohol  use 
• Counsel on the avoidance of pregnancy for women of child-bearing potential 
• Counsel on the avoidance of botulinum toxin, vaccines  and drugs listed in section 6.8. 
7.2. Visit 2: Baseline  (Day 0) 
Subjects meeting inclusion/exclusion criteria  will be admitted to the clinical unit the day of the 
injection  and the following procedures will be performed prior to study drug administration : 
• Review inclusion/exclusion criteria to ensure the subject remains eligible for enrollment  
• Update medical history  
• Review and update concomitant m edications  
• Perform abbreviated  physical  examination  
• Obtain vital s igns 
• Perform Breathalyzer  test to detect  recent alcohol use 
• For women , a urine hCG test will be done.  The results must be confirmed to be negative 
before dosing 
• Obtain urine sample for toxicology 
• Obtain blood samples for 
o Baseline serum PK  (prior to injection and at the completion of the 
injection and 2hr, 4hr, and 8 hr post dosing for subjects in Cohorts 1-3)  
o Baseline serum PK (prior to injection and at 6 hours post-injection for 
subjects in Cohort 4) 
o Serum sample to store for future use samples (for subjects who consent) 
o MNA (prior to injection for subjects in Cohorts 1-3) 
Protocol: G03-52-01.001 Version 3.0 
 September 7, 2021 
Ology Bioservices, Inc.  63 Proprietary  
 o MNA (prior to injection and at 2 hours post- injection  (optional) for 
subjects in Cohort 4)  
o ADA (prior to injection for all subjects)  
o Hypersensitivity panel  
o Clinical Safety Labs  
• Randomize the subject and obtain study product from the pharmacy 
• Perform IM Administration of study product 
• Assessment of AEs and SAEs after administration of study product 
• The subject  is eligible for discharge after all assessments have been performed, including 
the 8-hour post injection blood draw and there are no signs of anaphylaxis. 
7.3. Visit 3:  Out-patient Follow-up (24 hour s/Day 1 ) 
• Obtain vital signs  
• Review and update concomitant medications  
• Perform symptom directed PE  
• Obtain blood samples for the following: 
o PK measurement at 24 hours (+/ - 2 hours)   
• Counsel women of child-bearing potential on the avoidance of pregnancy  
• Counsel the subject not to receive any botulinum toxin preparation (e.g., Botox) for 4 
months after injection .   
• Assessment  of AEs  and SAEs   
7.4. Visit 4: Out -patient follow -up Visit (48 hour s/Day 2) 
• Obtain vital signs  
• Review and update c oncomitant medications  
• Perform symptom directed PE  
• Obtain blood samples for the following: 
• PK measurement at 48 hours (+/ - 2 hours)  Counsel women of child-bearing potential on 
the avoidance of pregnancy  
• Counsel the subject not to receive any botulinum toxin preparation (e.g., Botox) for 4 months after injection    
• Assessment of AEs and SAEs  
Protocol: G03-52-01.001 Version 3.0 
 September 7, 2021 
Ology Bioservices, Inc.  64 Proprietary  
 7.5. Visit 5: Out -patient Follow -up (72 hour s) Cohorts 1-3 
• Obtain vital signs  
• Review and update c oncomitant medications  
• Perform symptom directed PE  
• Obtain blood samples for the following: 
o PK measurement at 72 hours (+/ - 2 hours)   
• Counsel women of child-bearing potential on the avoidance of pregnancy  
• Counsel the subject not to receive any botulinum toxin preparation (e.g., Botox) for 4 
months after injection.    
• Assessment of AEs and SAEs  
7.6. Visit 6: Out -patient Follow -up (Day 4) 
• Obtai n vital signs  
• Review and update concomitant m edications  
• Perform symptom directed PE  
• Obtain blood samples for the following: 
o PK measurement  
o MNA   
• Obtain urine sample urine HCG for women of child bearing potential 
• Counsel women of child- bearing potential on the avoidance of pregnancy  
• Counsel the subject not to receive any botulinum toxin preparation (e.g., Botox) for 4 months after injection .   
• Assessment of AEs and SAEs 
7.7. Visit 7: Out -patient Follow -up (Day 8± 1) 
• Obtain vital signs  
• Review and update concomitant m edications  
• Perform sy mptom directed PE  
• Obtain blood samples for the following: 
o Clinical Safety Labs  
o PK measurement  
o Serum sample to store for future use (if subject gave consent) 
• Counsel women of child-bearing potential on the avoidance of pregnancy  
Protocol: G03-52-01.001 Version 3.0 
 September 7, 2021 
Ology Bioservices, Inc.  65 Proprietary  
 • Counsel the subject not to receive any botulinum toxin preparation (e.g.  Botox) for 4 
months after injection  
• Assessment of AEs and SAEs 
 
7.8. Visit 8: Out-patient Follow -up (Day 15± 1) 
• Obtain vital signs  
• Review and update concomitant medications  
• Perform symptom directed PE  
• Obtain blood samples for the following: 
o Clinical Safety Labs  
o PK measurement  
o ADA (Cohorts 1-3 only) 
• Assessment of AEs and SAEs 
• Counsel women of child-bearing potential on the avoidance of pregnancy  
• Counsel the subject not to receive any botulinum toxin preparation (e.g.  Botox) for 4 
months after injection  
• Assessment of COVID -19 vaccination status  
7.9. Visit 9:  Out-patient  Follow -up (Day 30 ± 1) 
• Obtain vital signs  
• Review and update concomitant medications  
• Perform symptom directed PE  
• Obtain blood samples for the following: 
o Clinical Safety Labs  
o PK measurement  
o MNA 
o ADA (Cohorts 1-3 only) 
o Serum sample to store for future use (if subject gave consent) 
• Assessment of AEs and SAEs 
• Counsel women of child- bearing potential on the avoidance of pregnancy  
• Counsel the subject not to receive any botulinum toxin preparation (e.g.  Botox) for 4 months after injection  
Protocol: G03-52-01.001 Version 3.0 
 September 7, 2021 
Ology Bioservices, Inc.  66 Proprietary  
 • Assessment of COVID -19 vaccination status.  
 
7.10. Visit 10: Out- patient  Follow -up (Day 45± 3) 
• Obtain vital signs  
• Review and update concomitant m edications  
• Perform sy mptom directed PE  
• Obtain blood samples for the following: 
o PK measurement  
o ADA  
o MNA (Cohort 4 only) 
• Perform urine pregnancy test on women of child- bearing potential  
• Assessment of AEs and SAEs 
• Counsel women of child-bearing potential on the avoidance of pregnancy  
• Counsel the subject not to receive any botulinum toxin preparation (e.g.  Botox) for 4 
months after injection  
• Assessment of COVID -19 vaccination status.  
 
7.11. Visit 11 : Out-patient Follow -up (Day 60 ± 3) 
• Obtain vital signs  
• Review and update concomitant medications  
• Perform symptom directed PE  
• Obtain blood samples for the following: 
o PK measurement  
o MNA 
o ADA  
• Assessment of AEs and SAEs 
• Counsel women of child-bearing potential on the avoidance of pregnancy  
• Counsel the subject not to receive any botulinum toxin preparation (e.g.  Botox) for 4 months after injection  
• Assessment of COVID -19 vaccination status.  
 
Protocol: G03-52-01.001 Version 3.0 
 September 7, 2021 
Ology Bioservices, Inc.  67 Proprietary  
 7.12. Visit 12 : Out-patient Follow -up (Day 90±3) 
• Obtain vital signs  
• Review and update concomitant medications  
• Perform symptom directed PE  
• Obtain blood samples for the following: 
o PK measurement  
o MNA 
o ADA  
• Assessment of AEs and SAEs 
• Counsel women of child-bearing potential on the avoidance of pregnancy  
• Counsel the subject not to receive any botulinum toxin preparation (e.g.  Botox) for 4 
months after injection  
• Assessment of COVID -19 vaccination status.  
 
7.13. Visit  13: Final Visit  / Early Termination Visit  for Cohorts 1-3 (Day 
120±3)  / Cohort 4 (Day 120± 3) 
• Obtain vital signs  
• Review and update c oncomitant medications  
• Perform symptom directed PE  
• Obtain blood samples for the following: 
o Clinical Safety labs  (Cohorts 1-3 Only) 
o PK measurement  
o MNA 
o ADA  
• Obtain urine sample for dipstick analysis  
• Perform urine pregnancy test on women of child- bearing po tential  
• Assessment of AEs and SAEs 
• Counsel women of child-bearing potential on the avoidance of pregnancy  
• Counsel the subject not to receive any botulinum toxin preparation (e.g.  Botox) for 4 months after injection  
• Assessment of COVID -19 vaccination status.  
Protocol: G03-52-01.001 Version 3.0 
 September 7, 2021 
Ology Bioservices, Inc.  68 Proprietary  
  
7.14. Visit 14: Final Visit/ Early Termination for Subjects in Cohort 4  
(Day 180±3)  
• Obtain vital signs  
• Review and update c oncomitant medications  
• Perform symptom directed PE  
• Obtain blood samples for the following: 
o Clinical Safety Labs   
o PK measurement  
o ADA  
• Obtain urine sample for dipstick analysis  
• Perform urine pregnancy test on women of child- bearing potential  
• Assessment of AEs and SAEs 
• Counsel women of child-bearing potential on the avoidance of pregnancy  
• Counsel the subject not to receive any botulinum toxin preparation (e.g.  Botox) for 4 
months after injection  
• Assessment of COVID -19 vaccination status.  
 
 
7.15. Unscheduled Visit  
A subject may return to the clinic for an unscheduled visit at any time.  The following activities 
at a minimum should be performed:  
• Obtain vital signs  
• Perform symptom directed PE as appropriate 
• Review and update concomitant m edications  
• Assessment of AEs and SAEs  
• Assessment of COVID -19 vaccination status.  
 
Protocol: G03-52-01.001 Version 3.0 
 September 7, 2021 
Ology Bioservices, Inc.  69 Proprietary  
 8. ASSESSMENT OF SAFETY 
Regulatory requirements including the FDA regulations and ICH Guidelines for GCP set forth 
safety monitoring and reporting responsibilities of sponsors and investigators to ensure the safety 
and protection of human subjects participating in clinical trials.   
Responsibilities  
Investigators participating in this clinical trial are responsible for and will: 
• evaluate subject safety including assessment of AE s for seriousness, severity, and 
causality;  
• notify the sponsor ( Ology Bioservices ) of SAEs immediately;  
• provide detailed written reports, including necessary documentation requested by the 
sponsor or IRB/Independent Ethics Committee (IEC), promptly followin g immediate 
initial reports, and; 
• Inform the IRB/IEC of AEs as required by applicable regulatory requirements. 
8.1. Specification of Safety Parameters  
Definitions  
Adverse events  
ICH E6 (R2) defines an AE as any untoward medical occurrence in a patient or clinical 
investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this  treatment.  An AE can therefore be any unfavorable and 
unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of medicinal (investigational) product, whether or not related to the medicinal (inve stigational) product.   
FDA defines an AE as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. 
 
Serious Adverse Events 
An SAE is any untoward medical occurrence that at any dose: 
• Results in  death , 
• Is life-threatening *,  
• Requires inpatient hospitalization or prolongation of existing hospitalization , 
• Congenital anomaly/birth defect; 
• Persistent or significant incapacity or substantial disruption of the ability to conduct 
normal life functions 
*Life -threatening adverse event.  An adverse event is considered “life-threatening” if, 
in the view of either the investigator or sponsor, its occurrence places the patient or 
Protocol: G03-52-01.001 Version 3.0 
 September 7, 2021 
Ology Bioservices, Inc.  70 Proprietary  
 subject at immediate risk of death.  It does not include an adverse event, had it 
occurred in a more severe form, might have caused death. 
Unexpected  
An adverse reaction, the nature or severity of which is not consistent with the applicable product 
information (e.g. Investigator’s Brochure for an unapproved investigational product or package insert/summary of product characteristics for an approved product). 
8.2. Methods and Timing for Assessing, Recording, and Analyzing Safety 
Parameters  
8.2.1. Adverse Events  
Any medical condition that is present at the time that the subject is screened should be 
considered as baseline and not reported as an AE.  However, if the condition increases in severity or frequency  at any time during the study, it should be recorded as an AE. 
All AEs must be graded for severity and relationship to study product based on the Investigator’s assessment.  
Severity  of adv erse events will be graded as follows based on the Investigator’s assessment 
unless otherwise specified in Appendix B.: 
Mild:   Events require minimal or no treatment and do not interfere with the subject’s daily 
activities.  
Moderate:   Events result in a low level of inconvenience or concern with therapeutic measures. 
Moderate events may cause some interference with functioning. 
Severe:   Events interrupt a subject’s usual daily activity and may require systemic dru g therapy 
or other treatment.  Severe events are usually incapacitating.  
8.2.2. Relationship to Study Product  
AEs and SAEs must be assessed by the investigator to determine relationship to study product.  
All AEs must have their relationship to study product asse ssed using the following terms.  In a 
clinical trial the study product must always be suspect.   
• Definitely Related:  There is a definite probability that the study product caused the 
adverse event.  
• Possibly Related:   There is a reasonable possibility that  the study product caused the 
adverse event.  Reasonable possibility means that there is evidence to suggest a causal relationship between the study product and the adverse event  
• Not Related : There is not a reasonable possibility that the administration of  the study 
product caused the event 
To help assess, the following factors may be considered: 
• Temporal relationship of the event to the administration of study product; 
Protocol: G03-52-01.001 Version 3.0 
 September 7, 2021 
Ology Bioservices, Inc.  71 Proprietary  
 • Whether an alternative etiology has been identified; 
• Biological plausibility;  
• Existing therapy and/or concomitant medications. 
8.3. Reporting Procedures  
8.3.1.  Adverse Events:  
AEs not meeting the criteria for “SAEs ,” will be captured on the appropriate case report form.  
Information to be collected for AEs  includes event description, time of onset, investigator 
assessment of severity, relationship to study product, date of resolution of the event, seriousness, 
and outcome. 
All AEs will be  followed until resolved or considered stable by the investigator.  
8.3.2. Serious Adverse Events  
The following procedures will apply to all serious adverse events: 
• The Principal Investigator will report any SAE to ICON PVSS within 24 hours of 
awareness.  
• ICON PVSS will perform an initial check of the SAE for missing elements and then inform 
the ICON MM, and the ISM. 
• ICON PVSS will record the information on the appropriate serious adverse event report 
form and send to DOD  PVG and to Ology Bioservices 
• Each SAE will be reviewed and followed to resolution or stability by a study physician 
• SAEs will be collected on each subject unti l his/her last study visit.  
 
Any AE that meets a protocol- defined serious criterion must be submitted immediately 
(within 24  hours of site awareness) on an SAE form to Ology Bioservices at the following 
address:  
 ICON PVSS  ICON plc PVSS   
 3rd Floor Marlow International, Parkway, Marlow, 
 Buckinghamshire, SL7 1YL, United Kingdom  
 SAE Email Address:  
ICON -Safety -
CentralReceipt@iconplc.com   
 ICON Medical Monitor:                                                                                         Uma Arumugam, MD  
                                                                                                                                                                                                                                                                ICON Early Phase Services  
Protocol: G03-52-01.001 Version 3.0 
 September 7, 2021 
Ology Bioservices, Inc.  72 Proprietary  
              820 West Diamond Ave., Suite 100 
             Gaithersburg, MD 20878, USA 
             SAE Phone:  410-294-2537 
             SAE Email Address:  uma.arumugam@iconplc.com   
 
ICON PVSS  will send AE/SAE information to Ology Bioservices , Inc.  
Ology Bioservices Ology Bioservices, Inc. 
 13200 NW Nano Court  
 Alachua, FL 32615, USA 
  SAE Hotline: 352-213-5757    
 SAE Fax Number:  888-551-1691 
 SAE Email Address: olo.safety@resilience.com  
 Other supporting documentation of the event may be r equested by  Ology Bioservices and should 
be provided as soon as possible.  
ICON plc PVSS will send SAEs with the ICON Drug Sa fety Physician  assessment  of causality, 
expectedness, and any impact on the benefit -risk ratio of the IMP to Ology Bioservices  and DO D 
PVG.  The ICON  medical monitor and clinical project  manager will be notified of the SAE by  
DOD PVG.  The ICON  medical monitor will review and assess the SAE for potential impact on 
study subject safety and protocol conduct.   
At any time after completion of the study, if the investigator becomes aware of an SAE that is 
suspected to be related to study product, the investi gator will report the event to ICON PVSS. 
8.3.3. Regulatory Reporting  
Following notification from the investigator, Ology Bioservices , the IND sponsor, will report 
any suspected adverse reaction that is both serious and unexpected to the FDA.  Ology Bioservices will report an adverse event as a suspected adverse reaction only if there is evidence 
to suggest a causal relationship between the drug and the AE.  Ology Bioservices  will notify 
FDA and all participating investigators (i.e., all investigators to whom the  sponsor is providing 
drug under its INDs or under any investigator’s IND) in an IND safety report of potential serious risks from clinical trials or any other source, as soon as possible, but in no case later than 15 
calendar days after the sponsor determ ines that the information qualifies for reporting as 
specified in 21 CFR Part 312.32. Ology Bioservices  will also notify FDA of any unexpected fatal 
or life -threatening suspected adverse reaction as soon as possible but in no case later than 7 
calendar day s after the sponsor’s initial receipt of the information. Relevant follow up 
information to an IND safety report will be submitted as soon as the information is available.  
Upon request from FDA, Ology Bioservices  will submit to FDA any additional data or 
Protocol: G03-52-01.001 Version 3.0 
 September 7, 2021 
Ology Bioservices, Inc.  73 Proprietary  
 information that the agency deems necessary, as soon as possible, but in no case later than 15 
calendar days after receiving the request.  
All SAEs  designated as “not related” to study product(s), will be reported to the FDA at least 
annually in a summary f ormat.  
8.3.4.  Reporting of Pregnancy 
Pregnancies that occur during the study period will be reported to the Sponsor on the Pregnancy Report form within five days of site awareness.  
Efforts will be made to follow all pregnancies occurring prior to 56 days post product 
administration  through to outcome, as described in the Safety Management Plan (e.g. delivery, 
spontaneous abortion or therapeutic abortion) . 
8.4. Type and Duration of Follow -up of Subjects after Adverse Events  
AEs will be followed until resolution or stab ility even if this extends beyond the study- reporting 
period.  Resolution of an AE is defined as the return to pretreatment status or stabilization of the 
condition with the expectation that it will remain chronic.  
Follow-up procedures, evaluations, and outcomes will be recorded on the subject's case report forms.  
8.5. Halting Rules  
8.5.1. Halting Criteria for the Study  
Study dosing can be halted  at any time if medic ally indicated.  Study dosing must be stopped, and 
a review of available safety data will be conducted by the S RC if any of the following occur: 
1. Death of a dosed subject following injection  and prior to the subject’s last visit that was 
not the result of trauma or accident, and possibly related to stu dy product. 
2. Occurrence of a life- threatening allergic/hypersensitivity reaction (anaphylaxis)  in any 
subject , manifested by bronchospasm with or without urticaria or angioedema or 
requiring hemodynamic support with pressor medications or mechanical ventilation.  
3.  One subject with an SAE. 
4. Two or more subjects with a Grade  3 AE in the same organ class (systemic toxicity, 
clinical laboratory tests or vital signs) regardless of relatedness to study drug.  An exception to this includes scenarios where there are obvious and acceptable physiological explanations for a Grade 3 abnormality (e.g., Grade 3 hematuria in a menstruating female).  
8.5.2. Dose Escalation Halting Criteria  
If any of the following criteria are met, escalation to the next planned dose cohort will not proceed until all available study data have been reviewed by the SRC.  
Protocol: G03-52-01.001 Version 3.0 
 September 7, 2021 
Ology Bioservices, Inc.  74 Proprietary  
 - More than 25% of the subjects in the cohort experience an AE, gra de 2 or above in 
the same organ class  
- A specific AE increases in severity from one cohort to the next AND the number of 
subjects  reporting that AE (at the higher severity level) in the cohort is the same or 
greater. An exception would be headaches going from a grade 1 to a grade 2. 
8.5.3. Evaluation of Dose Escalation 
The S RC must agree unanimously on the following criteria prior to dose escalation: 
• A review of all available unmonitored and uncoded safety data from at least 7 
subjects per cohort to Day 8 , at a minimum, demonstrate that study halting criteria 
as outlined in Section 9.5.2 have not been met. 
• A review of all available unmonitored and uncoded safety data from  at least 7 
subjects per cohort to Day 8 , at a minimum, demonstrate that no safety signals of 
any nature were observed . 
8.6. Safety Oversight  
8.6.1. Independent  Safety Monitor (ISM)  
The ISM is a physician with relevant expertise whose primary responsibility is to provide 
independent safety monitoring in a timely fashion.  The ISM will review SAEs and other AEs as 
needed and provide an independent assessment.   
8.6.2. ICON Medical Monitor  
The ICON Medical Monitor (MM)  is the clinical site’s primary point of contact for eligibility or 
safety related questions.  The ICON MM is responsible for liaising with Ology Bioservices  
Medical Monitor to ensure that all medical concerns are communicated  and will provide any 
potential pertinent medical communication update to the project team as needed.  Can make a 
recommendation that the SRC be convened to review any safety concerns.  
The ICON Medical Monitor will communicate with the Ology Bioservices Medical Monitor for 
any safety related questions.  The ICON MM will participate in the planned SRC meetings and can make a recommendation that the SRC be convened to review any safety concerns.  
8.6.3. Ology Bioservices  Medical Monitor  
The Ology Bioservices  Medical Monitor will be the main point of contact for the ICON MM 
including any safety-related questions or concerns.  The Ology Bioservices  MM will escalate any 
medical or safety concerns to the DOD as needed. The Ology Bioservices  MM will participate in 
the planned SRC meetings and can make a recommendation that the SRC be convened to review any safety concerns.  
8.6.4. Safety Review Committee (SRC)  
The SRC wi ll be composed of :  
Protocol: G03-52-01.001 Version 3.0 
 September 7, 2021 
Ology Bioservices, Inc.  75 Proprietary  
 • PI, or designee  
• Ology Bioservices  Medical Monitor  
• ICON  Medical Monitor or designee; 
Objective dose- escalation criteria and safety evaluations will be utilized.  F or Cohorts 1, 2, and 3 
the SRC will evaluate unmonitored and uncoded safety and tolerability data for at least 7 
subjects out to Day 8 to determine whether dose escalation can occur.  If none of the events 
described in 9.5.1 St udy Halting Criteria or in 9.5.2  Dose Escalation  Halting Criteria are 
observed, dose escalation will proceed.  Should any of the study halting criteria or dose 
escalation halting criteria be met, the S RC will meet to evaluate the data and recommend 
appropriateness of further dosing.  The SR C recommendation to advance to the next level will be 
documented and provided to all the appropriate parties (PI, Ology Bioservices , ICON  and D OD) 
involved with the study.  
If 2 or more subjects withdraw prior to Day 8, those subjects need to be replaced to ensure that 
data for at least 7 subjects is available for review.  
If 2 or more subjects withdraw prior to Day 60 or are not compliant with all PK draws through Day 15 , they may be replaced.   
If more than 2 subjects withdraw following the Day 8 SRC review of safety data, the site will attempt to replace those subjects in that dose group at the time of the next planned cohort. 
9. CLINICAL MONITORING  
9.1. Site Monitoring Plan  
Site monitoring is conducted to ensure that the human subject protection, study and laboratory procedures, study intervention administration, and data collection processes are of high quality and meet sponsor, GCP/ICH and, when appropriate, regulatory guid elines.  Site visits may be 
conducted by an authorized representative of ICON  or other regulatory agencies to inspect study 
data, subjects’ medical records, and eCRFs in accordance with ICH guidelines, GCP and the respective local and national government r egulations and guidelines. 
The investigator will permit authorized representatives of ICON  and the respective local and 
national health authorities to inspect facilities and records relevant to this study, if needed. 
A separate monitoring plan, to be developed by ICON , will describe protocol- specific items to be 
monitored. 
10. STATISTICAL CONSIDERATIONS  
10.1. Sample Size Considerations  
This is a Phase 1 study first in humans with four dosing Cohorts and no formal sample size 
calculations based on testing a statistica l hypothesis were constructed. Four dosing groups of ten  
each with eight participants  assigned the active group and two assigned to the control group are 
Protocol: G03-52-01.001 Version 3.0 
 September 7, 2021 
Ology Bioservices, Inc.  76 Proprietary  
 practical and provide sufficient information for a total sample size of 40 for a Phase 1 trial 
primarily designed to assess safety.  If ten subjects are studied, then the probability of at least 
one subject experiencing an event of toxicity can range from 0.728 to 0.996 assuming true event 
rates between 0.15 and 0.5 Additionally, if no events are observed in a cohort of six dosed 
subjects receiving  G03 -52-01 the upper bound of an exact 95% confidence interval for the true 
proportion is 0.46   
10.2. Planned Interim Analyses  
A blinded interim safety and PK analysis is planned for this study to analyze  all PK, ADA, and 
MNA samples  for Cohorts 1-3 through Day 60 and Day 120.  A second blinded interim safety 
analysis is planned to analyze all PK, ADA, and MNA samples for Cohort 4 through Day 90.  
Stopping cr iteria are for safety and are defined in section  9.5. 
10.3. Final Analysis Plan  
The ICH Guidance Document E9 (Statistical Principles for Clinical Trials) will be followed for 
all statistical content.  For categorical data, summaries of frequencies and percentages will be 
presented.  Summaries for continuous data will include minimum, lower quartile, median, mean, standard deviation, upper quartile, and maximum 
10.3.1. Analysis Populations 
All subjects who received study product will be included in the safety population and analyzed 
as treated . The PK a nalysis population will consist of all subjects who complete G03 -52-01 
injection and have sufficient evaluable PK samples for the estimation of PK parameters . 
10.3.2. Demographics and Baseline Characteristics  
Subject demographics and baseline characteristics will be summa rized by dose cohort and 
control group.   
10.3.3.   Safety Analysis Plan 
10.3.3.1. Adverse and Serious Adverse Events  
AEs will be coded using Medical Dictionary for Regulatory Activities
® (MedDRA). All AEs that 
occur after the initiation of study medication will be summariz ed using frequency counts and 
percentages. Summaries will be presented by dose cohort and control group. The following summaries will be presented for AEs and SAEs:  
• Overall (i.e., regardless of severity or relationship to treatment)  
• By severity grade (mil d, moderate, or severe) 
• By relationship to study medication  
• By MedDRA level hierarchy (system organ class and preferred term)  
Unless otherwise specified, at each level of subject summarization in reporting the incidence of the AEs, a subject will be counted once if the subject reported one or more events. If more than 
Protocol: G03-52-01.001 Version 3.0 
 September 7, 2021 
Ology Bioservices, Inc.  77 Proprietary  
 one occurrence of an event is reported, the event of the worst severity or the worst -case 
relationship assessment will be summarized.  
10.3.3.2. Additional Safety Analyses  
Vital signs, physical examinations, and clinical laboratory values, including change from 
baseline, will be summarized by dose cohort and control group. 
Descriptive summary statistics for laboratory data at admission (baseline value) and each 
applicable post- injection  visit, including change from the baseline value, will be calculated. 
Descriptive summary statistics for vital signs at screening (baseline valu e) and each applicable 
post- injection  visit, including change from the baseline value, will be calculated. Shift tables, 
showing individual subject changes from baseline will be presented for laboratory parameters 
using toxicity grading (Appendix B). Subjects with Graded values of vital sign and laboratory parameters will be identified in listings.  
10.3.4.   PK Analysis Plan 
PK parameters will be estimated for each of the six monoclonal antibodies separately using 
noncompartmental methods in WinNonlin or a similar software package. Parameters will be 
estimated by dose cohort. Summary statistics will include the mean, median, coefficient of 
variation, and range. When evaluable, estimated  PK parameters will include: 
• AUC
(0-t): Area under the concentration  time-curve to the last concentration above the lower 
limit of quantitation  
• Cmax: Maximum observed concentration 
• Tmax: Time of maximum observed concentration  
• Kel: Elimination rate constant 
• AUC (0-∞): Area under the concentration time- curve extrapolated to i nfinity 
• t1/2: Terminal elimination half -life 
• CL: Total c learance  
• Vz: Volume of distribution  
Additionally, multi-compartmental models will be considered based on inspection of 
concentration -time curves. If models are fit, base models will assume first-order elimination 
from the central compartment, and models will be parameterized in terms of clearance, volume 
of distribution and inter- compartmental rates. Standard objective goodness of fit measures will 
be used to determine the final model.  
10.3.5. Immunogenicity  
Immunogenicity will be measured by the development of antibody titers.  The presence of ADA will be measured over the course of the post -injection period. 
Protocol: G03-52-01.001 Version 3.0 
 September 7, 2021 
Ology Bioservices, Inc.  78 Proprietary  
 10.3.6.  Missing values and outliers 
All attempts will be made to collect all data per protocol.  No imputation will be performed for 
missing values. Outliers identified during the PK analysis will be discussed in the analysis report.  
Protocol: G03-52-01.001 Version 3.0 
 September 7, 2021 
Ology Bioservices, Inc.  79 Proprietary  
 11. SOURCE DOCUMENTS AND ACCESS TO SOURCE 
DATA/DOCUMENTS  
The site will maintain appropriate medical and research records for this trial, in compliance with 
ICH E6 (R2) GCP, Section 4.9, and regulatory and institutional requirements for the protection of 
confidentiality of subjects.  As part of participating in a D OD-affiliated, or ma nufacturer -
sponsored study, the site will permit authorized repre sentatives of the sponsor(s), DO D, and 
regulatory agencies to review (and, when required by applicable law, to copy) clinical records for 
the purposes of quality assurance reviews, audits, and evaluation of the study safety and 
progress. 
Forms for use as source documents will be derived from the electronic CRFs and will be 
provided by ICON .  Additional source data are all information, original records of clinical 
findings, observations, or other activities in a clinical trial necessary for the reconstruction and 
evaluation of the trial.  Examples of these original documents and data records include, but are 
not limited to, hospital records, clinical and office charts, laboratory notes, memoranda, 
pharmacy dispensing records, recorded data from automated instruments, copies or transcriptions certified after verification as being accurate and complete, microfiches, photographic negatives, 
microfilm or magnetic media, x -rays, and subject files and records kept at the pharmacy, 
laboratories, and medico- technical departments involved in the clinical trial.   If data is recorded 
directly into the eCRF with no paper source, then that data should be listed as being a direct 
electronic data entry with no paper source available.  
12. QUALITY CONTROL AND QUALITY ASSURANCE  
Following a written D OD-accepted site quality management plan, the investigational site is 
responsible for conducting routine quality assurance and quality control activities  to internally 
monitor study progress and protocol compliance.  The PI will provide direct access to all trial-related sites, source data/documents, and reports for the purpose of monitoring and auditing by the sponsor, and inspection by local and regulatory authorities. The PI will ensure all study 
personnel are appropriately trained and applicable documentations are maintained on site.  
Clinical monitors will verify that the clinical trial is conducted, and data are generated, 
documented (recorded), and reported in compliance with the protocol, GCP, and the applicable 
regulatory requirements.  Clinical monitoring reports will be submitted to Ology Bioservices . 
ICON  will implement quality control procedures beginning with the data entry system and 
generate data quality control checks that will be run on the database. Any missing data or data anomalies will be communicated to the site(s) for clarification and resolution.  
 
      
Protocol: G03-52-01.001 Version 3.0 
 September 7, 2021 
Ology Bioservices, Inc.  80 Proprietary  
  
13. ETHICS/PROTECTION OF  HUMAN SUBJECTS  
13.1. Ethical Standard  
The investigator will ensure that this study is conducted in full conformity with principles of the 
Belmont Report:  Ethical Principles and Guidelines for the Protection of Human Subjects of 
Research of the National Commission for the Protection of Human Subjects of Biomedical and 
Beha vioral Research (April 18, 1979) and codified in 45 CFR 46, 21 CFR 50 and 56, and ICH 
E6(R2); 62 Federal Regulations 25691 (1997), if applicable.  The investigator’s Institution will 
hold a current Federal Wide Assurance (FWA) issued by the Office of Human  Research 
Protection for federally funded research.  
13.2. Institutional Review Board  
The site  will provide for the review and approval of this protocol and the associated informed 
consent documents, by an appropriate ethics review committee or IRB listed on the FWA.  Any amendments to the protocol or consent materials must also be approved before they are placed into use unless change is for the safety of the subject.  Only those IRB members who are 
independent of the investigators and the sponsor should provide an opinion on study related 
matters.  Verification of IRB approval of the protocol and the written informed consent will be transmitted by the investigator or designee prior to the shipment of study product.  No deviations 
from or changes to the protocol will be initiated without prior approval of an appropriate 
amendment unless change is for the safety of the subject.  
13.3. Informed Consent Process  
13.3.1.   Informed Consent  
The written consent document will embody the elements of informed consent as described in the Declaration of Helsinki and will adhere to the ICH Harmonized Tripartite Guideline for Good 
Clinical Practice.  Informed consent should be implemented before any protocol- specified 
procedures or interventions are carried out.  Informed consent will be obtained in accordance with 21 CFR 50.25 and 45 CFR 46.  Information should be presented both orally and in written form.  
An investigator or designee will describe the protocol to potential subjects face -to-face.  The 
Subject Information and Consent Form may be read to the subjects, but, in any event, the 
investigator shall give the subjects ample opportunity to inquire about details of the study and 
ask any questions before the signing and dating the consent form. 
Study staff must inform subjects that the trial involves research, and explain the purpose of the 
trial, those aspects of the trial that are experimental, any expected benefits, all possible risks 
(including a statement that the particular treatment or procedure may involve risks to the subject or to the embryo or fetus, if the subject is or may become pregnant, that are currently 
unforeseeable), the expected duration of the subject’s participation in the trial, the procedures of 
Protocol: G03-52-01.001 Version 3.0 
 September 7, 2021 
Ology Bioservices, Inc.  81 Proprietary  
 the research study, including all invasive procedures, and the probability for random assignment 
to treatment groups.  Subjects will be informed that they will be notified in a timely manner if 
information becomes available that may be relevant to their willingness to continue participation in the trial.  They must also be informed of alternative procedures that may be available, and the 
important potential benefits and risks of these available alternative procedures.  Subjects must 
receive an explanation as to whether any compensation and any medical treatments are available if injury occurs, and, if so, what they consist of, or where further information may be obtained.  
Subjects must be informed of the anticipated financial expenses, if any, to the subject for participating in the trial, as well as any anticipated prorated payme nts, if any, to the subject for 
participating in the trial.  They must be informed of whom to contact (e.g., the investigator) for 
answers to any questions relating to the research project.  Information will also include the 
foreseeable circumstances and/o r reasons under which the subject’s participation in the trial may 
be terminated.  The subjects must be informed that participation is voluntary and that they are 
free to withdraw from the study for any reason at any time without penalty or loss of benefits to 
which the subject is otherwise entitled.  
Neither the investigator, nor the trial staff, should coerce or unduly influence a subject to 
participate or continue to participate in the trial.  The extent of the confidentiality of the subjects’ 
records must be defined, and subjects must be informed that applicable data protection legislation will be followed.  Subjects must be informed that the monitor(s), auditors(s), IRB, 
DOD, Ology Bioservices , and regulatory authority(ies) will be granted direct access to the 
subject’s original medical records for verification of clinical trial procedures and/or data without 
violating the confidentiality of the subject, to the extent permitted by the applicable laws and 
regulations, and that, by signing a written informe d consent form, the subject is authorizing such 
access.  Subjects must be informed that records identifying the subject will be kept confidential, 
and, to the extent permitted by the applicable laws and/or regulations, will not be made publicly 
available and, if the results of the trial are published, the subject’s identity will remain 
confidential. 
Consent forms must be in a language fully comprehensible to the prospective subjects.  Informed 
consent shall be documented by the use of a written consent form approved by the IRB and 
signed and dated by the subject and the person who conducted the informed consent discussion.  The signature confirms that the consent is based on information that has been provided and all 
questions have been answered to the prospective participant’s satisfaction.  Each subject’s signed 
informed consent form must be kept on file by the investigator for possible inspection by Regulatory Authorities and/or the sponsor and Regulatory Compliance persons.  The subject 
should receive a copy of the signed and dated written informed consent form and any other 
written information provided to the subjects and  should receive copies of any signed and dated 
consent form updates and any amendments to the written information provided to subjects. 
13.4. Exclusion of Women, Minorities, and Children (Special Populations)  
Children are excluded for safety reasons.  
Protocol: G03-52-01.001 Version 3.0 
 September 7, 2021 
Ology Bioservices, Inc.  82 Proprietary  
 13.5. Subject Confidentiality  
Subject confidentiality is held strictly in trust by the participating investigators, their staff, and 
the sponsor and their agents.  This confidentiality is extended to cover testing of biol ogical 
samples in addition to the clinical information relating to participating subjects.  
The study protocol, documentation, data, and all other information generated will be held in strict confidence.  No information concerning the study,  or the data will be released to any 
unauthorized third party without prior written approval from the sponsor. 
The study monitor or other authorized representatives of the sponsor may inspect all document s 
and records required to be maintained by the Investigator, including, but not limited to, medical 
records (office, clinic, or hospital) and pharmacy records for the subjects in this study.  The clinical study site will permit access to such records.  
13.6. Study Discontinuation  
Ology Bioservices  has the right to terminate this study  or the site’s participation at any time.  
Reasons for terminating the study may include, but are not limited to, the following: 
• Incidence or severity of adverse events indicates a potential health hazard; 
• Data recording is inaccurate or incomplete;  
• Investigator does not adhere to the protocol or applicable regulatory guidelines in conducting the study. 
13.7. Future Use of Stored Specimens  
Samples will be collected as outlined in the proto col.  Subjects will be given a choice during the 
informed consent process to have their residual linked samples stored indefinitely for future research, have their residual samples de-linked from any subject information and stored 
indefinitely, or have their residual linked samples destroyed at completion of the study.  The use 
of long-term stored linked samples will be conducted under the restrictions regarding confidentiality, as outlined in the preceding paragraphs. 
Only coded specimens will be sent to the sponsor with the code identifiers maintained by the 
principal investigator.  Any future research studies will utilize only the residual long- term stored 
specimens from subjects consenting to future use.  
14. DATA HANDLING AND RECORD KEEPING  
The investigator is responsible to ensure the accuracy, completeness, legibility, and timeliness of the data reported.  All data collection forms should be completed in a neat, legible manner to ensure accurate interpretation of data.  Black ink is required to ensure clar ity of reproduced 
copies.  When making changes or corrections, cross out the original entry with a single line, and initial and date the change.  Do not erase, overwrite, or use correction fluid or tape on the original. 
Protocol: G03-52-01.001 Version 3.0 
 September 7, 2021 
Ology Bioservices, Inc.  83 Proprietary  
 Copies of the electronic CRF (eCRF) will be provided for use as source documents and 
maintained for recording data for each subject enrolled in the study.  Data reported in the eCRF 
derived from source documents should be consistent with the source documents or the discrepancies should be explained. 
Ology Bioservices  and/or its designee will provide guidance to investigators on making 
corrections to the data collection forms/source documents and eCRFs. 
14.1. Data Management Responsibilities  
All source documents and laboratory reports must be reviewed by the clinical team and data 
entry staff, who will ensure that they are accurate and complete.  Adverse Events must be 
graded, assessed for severity and causality, and reviewed by the site Principal Investigator or designee.  
Data collection is the responsibility of the clinical trial staff at the site under the supervision of the site Principal Investigator.  During the study, the investigator must maintain complete and accurate documentation for the study. 
ICON will serve as the Statistical and D CC for this study, and will be responsible for data 
management, quality review, analysis, and reporting of the study data. 
14.2. Data Capture Methods 
Clinical data (including AEs, concomitant medications, and reactogenicity data) and clinical 
laboratory data wil l be entered into a 21CFR11- compliant Internet Data Entry System provided 
by ICON .  The data system includes password protection and internal quality checks, such as 
automatic range checks, to identify data that appear inconsistent, incomplete, or inaccura te.  
Clinical data will be entered directly from the source documents.  
14.3. Types of Data  
Data for this study will include  clinical safety assessments, safety laboratory assessments , 
immunology and PK. 
14.4. Timing/Reports  
A final report will be prepared following the availability of all the safety and immunogenicity data.  
14.5. Study Records Retention  
Study files (except for future use consent forms) must be maintained for a minimum of two years after the last approval of a marketing application in an ICH region and until there are no pending or contemplated marketing applications in and ICH region or at least 2 years have elapsed since 
the formal discontinuation of clinical development of the investigational product.  These 
documents should be retained for a longer period, however, if required by local regulations. No records will be destroyed without the written consent of the sponsor, if applicable.  It is the 
Protocol: G03-52-01.001 Version 3.0 
 September 7, 2021 
Ology Bioservices, Inc.  84 Proprietary  
 responsibility of the sponsor to inform the investigator when these documents no longer need to 
be retained.  Consent forms for future use will be maintained as long as the sample exists.  
14.6. Protocol Deviations 
A protocol deviation is any noncompliance with the clinical trial protocol, GCP, or protocol-specific MOP requirements.  The noncompliance may be either on the part of the subject, the 
investigator, or the study site staff.  As a result of deviations, corrective actions are to be 
developed by the site and implemented promptly. 
These practices are consistent with ICH E6 (R2): 
4.5 Compliance with Protocol, Sections 4.5.1, 4.5.2, and 4.5.3 
5.1   Quality Assurance and Quality Control, Section 5.1.1 
5.20   Noncompliance, Sections 5.20.1, and 5.20.2. 
It is the responsibility of the site PI/study staff to use continuous vigilance to identify and report 
deviations within five working days of identification of the protocol deviation, or within five working days of the scheduled protocol-required activity.  All deviations must be promptly reported to ICON/ Ology Bioservices . 
All protocol deviations, as defined above, must be addressed in study subject source documents.  A completed copy of the Protocol Deviation Form must be maintained in the Regulatory File , as 
well as in the subject's source document.  Protocol deviations must be sent to the local IRB/IEC per their guidelines.  The site PI/study staff is responsible for knowing and adhering to their IRB requirements.  
15. PUBLICATION POLICY 
All manuscripts resulting from this trial will be reviewed by representatives from the sites, DOD 
and the product manufacturer.  Each institution will have at least thirty days to review the 
publication prior to submission. 
The International Committee of Medical Journal Editors (ICMJE) member journals have adopted 
a trials -registration policy as a condition for publication.  This policy requires that all clinical 
trials be registered in a public trials registry such as ClinicalTria ls.gov , which is sponsored by the 
National Library of Medicine (NLM).  Other biomedical journals are considering adopting 
similar policies.  This trial will be registered in NLM in accordance with the new NLM 
requirements under the Food and Drug Administra tion Amendments Act ( FDAAA). 
*Journal Citation :  
De Angelis C , Drazen JM , Frizelle FA , Haug C , Hoey J , Horton R , et al. Clinical trial 
registration: a statement from the International Committee of Medical Journal Editors. N Engl J Med. 2004;351:1250-1. 
Protocol: G03-52-01.001 Version 3.0 
 September 7, 2021 
Ology Bioservices, Inc.  85 Proprietary  
 16. LITERA TURE REFERENCES  
1. Werner SB, Passaro D, McGee J, Schechter R and Vugia DJ. Wound botulism in 
California, 1951-1998: recent epidemic in heroin injectors. Clin Infect Dis  
2000;31(4):1018-24. 
 
2. Lacy DB and Stevens RC. Sequence homology and structural analysis of the clostridial neurotoxins. J Mol Biol  1999;291(5):1091-104. 
 
3. Barash JR and Arnon SS.  A novel strain of clostridium botulinum that produces type b 
and type h botulinum toxins. J Infect Dis. 2014;209(2):183-91.  
4. Arnon SS, Schechter R, Inglesby TV, et al. Botulinum toxin as a biological weapon: medical and public health management. JAMA  2001;285(8):1059-70.  
5. CDC. Botulism in the United States, 1899-1996. Handbook for epidemiologists, clinicians, and laboratory workers. Atlanta, GA, Centers for Disease Control and Prevention 1998. 
 
6. Hughes JM, Blumenthal JR, Merson MH, Lombard GL, Dowell VR, Jr. and Gangarosa 
EJ. Clinical features of types A and B food-borne botulism. Ann Intern Med  1981;95(4):442-5.  
7. Seals JE, Snyder JD, Edell TA, et al. Restaurant -assoc iated type A botulism: transmission 
by potato salad. Am J Epidemiol 1981;113(4):436-44.  
8. NIAID. NIAID Biodefense research agenda for CDC category A agents. NIAID. Washington, D.C., U.S. Department of Health and Human Services.  2002.  
9. Black RE and Gunn RA. Hypersensitivity reactions associated with botulinal antitoxin. 
American Journal of the Medical Sciences  1980;69:567-70.  
10. Hibbs RG, Weber JT, Corwin A, et al. Experience with the use of an investigational F(ab')2 heptavalent botulism immune globulin of equine origin during an outbreak of type E botulism in Egypt. Clin Infect Dis  1996;23(2):337-40. 
 
11. Arnon SS, Schechter R, Maslanka SE, Jewell NP and Hatheway CL. Human botulism 
immune globulin for the treatment of infant botulism. N Engl J Med  2006;354:462-71.  
Protocol: G03-52-01.001 Version 3.0 
 September 7, 2021 
Ology Bioservices, Inc.  86 Proprietary  
 12. CDC. Notice of CDC's discontinuation of investigational pentavalent (ABCDE) 
botulinum toxoid vaccine for workers at risk for occupational exposure to botulinum toxins. Morbidity and Mortality Weekly Report  2011;60(42):1454-5. 
 
13. CDC. Inves tigational heptavalent botulinum antitoxin (HBAT) to replace licensed 
botulinum antitoxin AB and investigational botulinum antitoxin E Morbidity and 
Mortality Weekly Report  2010;59(10):299.  
14. Fagan RP, Neil KP, Sasich R, et al. Initial recovery and rebound of type f intestinal 
colonization botulism after administration of investigational heptavalent botulinum 
antitoxin. Clin Infect Dis  2011;53(9):e125-8. 
15. Nowakowski A, Wang C, Powers DB, et al. Potent neutralization of botulinum 
neurotoxin by recombinant oligoclonal antibody. Proc Natl Acad Sci U S A 2002;99(17):11346-50. 
Protocol: G03-52-01.001 Version 3.0 
 September 7, 2021 
 ______________________________________________________________________________________________________  
 
Ology Bioservices, Inc.  87 Proprietary  
 APPENDICES
Protocol: G03-52-01.001                    Version 3.0 
 September 7, 2021 
 ______________________________________________________________________________________________________  
Ology Bioservices, Inc.  88 Proprietary  
  APPENDIX A: SCHEDULE  OF EVENT S 
Study Visit  Screening1 
 
01 Baseline  
 
02  
 
03  
 
04  
 
05 
Cohort 
1-3 
Only   
 
06  
 
07  
 
08 
  
 
09  
 
10  
 
11  
 
12  
 
13 / 
Early 
Term  14 
Cohort 
4 Only  
Study Day (Window)  -28 to -3 0 24 hr  48 
hr 72 hr  4 8±1 15±1  30±1  45±3  60±3  90±3  120±3  180±3 
Review Inc/ ExcI Criteria  X X             
Review Medical History  X X             
Review Contraception/menses  X              
Perform Abbreviated PE3 X X             
Perform Symptom -Directed PE13  X X X X X X X X X X X X X 
Obtain Vital Signs4 X X X X X X X X X X X X X X 
Obtain  Screening Labs5 X              
Obtain Clinical Safety Labs,6  X     X X X    X,18 X 
Serum β -HCG  X7              
Urine pregnancy test   X    X    X   X18 X 
Urine Dipstick8  X X           X18 X 
Urine Toxicology  X X             
Breathalyzer test  X X             
Immunogenicity (ADA)14  X      X X X X X X X 
Hypersensitivity Panel15  X             
12-lead ECG9 X              
Viral Serology10 X              
PK samples11  X   X X X X X X X X X X X X 
MNA   X16    X   X X17 X X X  
Concomitant Medications2 X X   X X X X X X X X X X X X 
Randomization   X             
Study Drug Administration   X             
Future Use Sample12  X     X  X       
Protocol: G03-52-01.001                    Version 3.0 
 September 7, 2021 
 ______________________________________________________________________________________________________  
Ology Bioservices, Inc.  89 Proprietary  
  Study Visit  Screening1 
 
01 Baseline  
 
02  
 
03  
 
04  
 
05 
Cohort 
1-3 
Only   
 
06  
 
07  
 
08 
  
 
09  
 
10  
 
11  
 
12  
 
13 / 
Early 
Term  14 
Cohort 
4 Only  
Study Day (Window)  -28 to -3 0 24 hr  48 
hr 72 hr  4 8±1 15±1  30±1  45±3  60±3  90±3  120±3  180±3 
Counsel on the avoidance of 
pregnancy  X  X X X X X X X X X X X X 
Counsel on avoidance of 
botulinum toxin and vaccines  X  X X X X X X X X X X X X 
AE Review   X X X X X X X X X X X X X 
SAE Review   X X X X X X X X X X X X X 
1. Screening will be completed within 28 days prior to administration of study drug and may require more than one visit.  
2. Concomitant medications  including all of the following: prescription drugs, over -the –counter drugs, herbs, vitamins, nutritional supplements, illicit and recreational substance use, birth 
control information.  
3. PE includes height and weight at screening.     
4. Vital Signs to includ e sitting diastolic and systolic blood pressure, heart rate, and oral temperature.  Vital signs will be checked just before injection and every visit.  
5. Subjects should be fasting for Screening Laboratory Tests that will include hemoglobin, WBC with different ial, absolute neutrophil count and platelet count. MCV, MCH, MCHC, RDW, 
MPV, which are included in a complete blood count with differential, will not be graded, serum creatinine, BUN, calcium, total bilirubin, direct bilirubin, indirect bilirubin, alkaline  
phosphatase, PT, PTT, INR, ALT, AST, sodium, potassium, and total CK.  Subjects in cohort 4 only will have NX02 levels drawn at screening  
6. Subjects should be fasting for Clinical Safety Laboratory Tests that will include hemoglobin, WBC with differential, absolute  neutrophil count and platelet count. MCV, MCH, MCHC, 
RDW, MPV, which are included in a complete blood count with differential, will not be graded, serum creatinine, BUN, calcium, total bilirubin, direct bilirubin, indirect bilirubin, alkaline 
phosphatase, PT, PTT, INR, ALT, AST, sodium, potassium, and total CK.  
7. A serum pregnancy test will be obtained for all women of reproductive capacity.  Results must be confirmed as negative before study product is dosed.   
8. A urine dipstick will be done to evaluate for presence of protein, glucose or blood in urine. If dipstick is abnormal, a comp lete urinalysis with microscopic will be performed.  
9. A 12 -lead ECG will be done during screening.  
10. Viral Serology includes HIV, HBsAg and antibody to HCV.  
11. Subjects in Cohorts 1- 3 will have PK samples taken at the following times: pre -dose, 2, 4, 8, 24, 48, and 72 hours post injection and on days 4, 8, 15, 30 , 45, 60, 90, and 120 . .   Subjects in 
Cohort 4 will have PK samples taken at pre -dose, 6 hours post -dose, and on days 1, 2, 4, 8, 15, 30, 45, 60, 90, 120, and 180 . 
12. Serum from subjects who give consent will be stored for future use.  On Days 0, 8, and 30 . 
13. The subject will be under direct observation during at least the initial 30 minutes of the injection.  A physical examination  will be performed at approximately 30 minutes after starting the 
injection and again in response to subject symptoms which will in clude the following: General appearance including alertness and any difficulty breathing, HEENT, Chest, Heart, Skin and 
Joints.  
14. Draw prior to dosing at baseline  for all Cohorts. Subjects in Cohorts 4 will not have ADA blood draws on Day 15 or Day 30. C ohort 4 will have ADA drawn on follow - up Days 45, 60, 90, 120 and 
180. 
        15.  The Hypersensitivity Panel  includes cytokine and complement panels, IgE, and tryptase.  Draw 14ml prior to dosing. If a subj ect develops anaphylaxis or anaphylactoid react ion, an additional 
14 mL sample will be drawn during the event and another will be drawn after the event . 
16. MNA: To be drawn pre -dose for All Cohort s.  Cohort 4 subjects will also have a 2 -hour post dose  optional  (+/- 10 minutes) draw.  
18. Cohorts 1 -3 only.  
Protocol: G03-52-01.001                    Version 3.0 
 September 7, 2021 
 ______________________________________________________________________________________________________  
Ology Bioservices, Inc.  90 Proprietary  
  APPENDIX B: TOXICITY GRADING  
Clinical Adverse Events  
VITAL SIGNS  Mild  
(Grade 1)  Moderate  
(Grade 2)  Severe  
Grade 3  
Fever - °C 
  
 38.0-38.4 
  
 38.5-38.9 
  
 >38.9 
  
 
Tachycardia - bpm 101-115 116-130 >130 or ventricular 
dysrhythmias  
Bradycardia – bpm 
• Baseline ≥60  
OR, if  
                Baseline <60  •   50-54  
OR, if Baseline 
<60,  
•   45-50 •    45-49  
OR, if baseline <60,  
•         40-44 •   <45  
OR, if baseline <60  
•     <40 
Hypertension (systolic) - mmHg  141-150 151-160 >160 
Hypertension (diastolic) - mmHg  91-95 96-100 >100 
Hypotension (systolic) - mmHg  85-89 80-84 <80 
Tachypnea – breaths per min  23-25 26-30 >30 
CARDIOVASCULAR  Mild  
(Grade 1)  Moderate  
(Grade 2)  Severe  
(Grade 3)  
Arrhythmia     Asymptomatic; transient signs; 
no medical intervention required  Recurrent/persistent; 
symptomatic medical 
intervention required  
Hemorrhage, Blood Loss  Estimated blood 
loss ≤100 mL  Estimated blood loss >100 mL; 
no transfusion required  Transfusion required  
QTc (Fridericia’s correction)1 
 
 Asymptomatic, 
QTc interval 450-479 msec  Asymptomatic; QTc interval 480 
to 499 msec OR Increase in interval 30 -59 msec above 
baseline  Asymptomatic; QTc 
interval ≥ 500 msec OR Increase in interval ≥ 60 msec above baseline  
PR Interval (prolonged)1 PR interval 
0.21- 0.25 sec  PR interval >0.25  Type II 2nd degree AV 
block OR Ventricular pause >3.0 sec 
RESPIRATORY    Mild  
(Grade 1)  Moderate  
(Grade 2)  Severe  
(Grade 3)  
Cough  Transient; no 
treatment  Persistent cough  Interferes with daily 
activities  
Bronchospasm, Acute  Transient; no 
treatment; FEV1 71- 80% 
of predicted 
peak flow  Requires medical intervention; 
normalizes with bronchodilator; FEV1 60- 70% of predicted peak 
flow  No normalization with 
bronchodilator; FEV1 <60% of predicted peak flow 
Dysp nea   Does not 
interfere with 
usual and social 
activities  Interferes with usual and social 
activities; no treatment  Prevents daily and 
usual social activity OR requires treatment  
GASTROINTESTINAL   Mild  
(Grade 1)  Moderate  
(Grade 2)  Severe  
(Grade 3)  
                                                 
1Inclusion dependent upon protocol requirements.  
Protocol: G03-52-01.001                    Version 3.0 
 September 7, 2021 
 ______________________________________________________________________________________________________  
Ology Bioservices, Inc.  91 Proprietary  
  Nausea  No interference 
with activity  Some interference with activity  Prevents daily activities  
Vomiting  No interference 
with activity 
OR 1 -2 
episodes/24 
hours  Some interference with activity 
OR >2 episodes/24 hours  Prevents daily activity 
OR requires IV  
hydration OR requires medical intervention  
Diarrhea  2-3 loose or 
watery stools or <400 g/24 hours  4-5 loose or watery stools or 
400-800 g/24 hours  ≥6 loose or watery 
stools or >800g/24 hours OR requires IV hydration OR requires 
medical intervention  
REACTOGENICITY     
LOCAL REACTIONS  Mild  
(Grade 1)  Moderate  
(Grade 2)  Severe  
(Grade 3)  
Pain – experienced without 
touching the injection site 
(spontaneous discomfort)  Does not 
interfere with 
activity  Repeated use of non -narcotic 
pain reliever >24 hours OR 
interferes with activity  Any use of narcotic 
pain reliever OR 
prevents daily activity  
Tenderness – hurts only when 
injection site is touched, or the 
arm is moved  Discomfort only 
to touch  Discomfort with movement  Significant discomfort 
at rest  
Pruritus (Itching)  Does not 
interfere with 
daily activity  Interferes with daily activity  Prevents daily activity  
Ecchymosis (Bruising)*  Does not 
interfere with 
daily activity  Interferes with daily activity  Prevents daily activity  
Erythema (Redness)* Does not 
interfere with 
daily activity  Interferes with daily activity  Prevents daily activity  
Induration 
(Hardness)/Swelling* Does not 
interfere with 
daily activity  Interferes with daily activity  Prevents daily activity  
Nodule Does not 
interfere with 
daily activity  Interferes with daily activity  Prevents daily activity  
Ulcer Does not 
interfere with 
daily activity  Interferes with daily activity  Prevents daily activity  
Ecchymosis (Bruising)* 25 mm – 
50 mm 51 mm – 100 mm  >100 mm  
Erythema (Redness)* 25 mm – 
50 mm 51 mm – 100 mm  >100 mm  
Induration 
(Hardness)/Swelling* 25 mm – 
50 mm 51 mm – 100 mm  >100 mm  
Nodule 25 mm – 
50 mm 51 mm – 100 mm  >100 mm  
Ulcer 1 mm – 50 mm 51 mm – 100 mm  >100 mm  
SYSTEMIC REACTIONS  Mild  
(Grade 1)  Moderate  
(Grade 2)  Severe  
(Grade 3) 
Allergic Reaction  Pruritus without 
rash  Localized urticaria OR requires 
oral therapy  Generalized urticaria; 
angioedema OR 
Protocol: G03-52-01.001                    Version 3.0 
 September 7, 2021 
 ______________________________________________________________________________________________________  
Ology Bioservices, Inc.  92 Proprietary  
  anaphylaxis OR 
requires epinephrine  
Headache  No interference 
with activity  Repeated use of non -narcotic 
pain reliever >24 hours OR some 
interference with activity  Significant; any use of 
narcotic pain reliever OR prevents daily activity OR requires 
triptans  
Fatigue  No interference 
with activity  Some interference with activity  Significant; prevents 
daily activity  
Myalgia  No interference 
with activity  Some interference with activity  Significant; prevents 
daily activity  
All Other conditions  Mild  
(Grade 1)  Moderate  
(Grade 2)  Severe  
(Grade 3)  
Illness or clinical AE (as 
defined according to applicable 
regulations)  No inte rference 
with activity  Some interference with activity 
not requiring medical 
intervention  Prevents daily activity 
and requires medical 
intervention  
*Will not be used as halting criteria  
  
Protocol: G03-52-01.001                    Version 3.0 
 September 7, 2021 
 ______________________________________________________________________________________________________  
Ology Bioservices, Inc.  93 Proprietary  
  Laboratory and Vital Signs Reference Ranges, Eligibility Ranges, and Toxicity Grading 
Laboratory Adverse Events* Mild  Moderate  Severe  ICON Normal Lab 
Values  (Grade 1)  (Grade 2)  (Grade 3)  
Blood, Serum, or Plasma  
Sodium (hyponatremia) – mEq/L  131-132 129-130 <129  133 – 143 
Sodium (hypernatremia) – 
mEq/L  144 – 145 146 – 147 >147  133 – 143 
Potassium (hyperkalemia) – 
mEq/L  5.2 – 5.4 5.5 – 5.6 >5.6 3.5 - 5.1 
Potassium (hypokalemia) – 
mEq/L  3.2-3.4 3.0 – 3.1 <3.0 3.5 - 5.1 
Glucose (hypoglycemia) – 
mg/dL  65 – 69 55 – 64 <55 70 – 105 
Glucose (hyperglycemia) – 
mg/dL Fasting  106 – 125 126 – 200 >200  70 – 105 
Blood Urea Nitrogen – mg/dL  21-26 27 – 31 > 31 6 – 20 
Creatinine (Male) – mg/dL  1.3 – 2.0 2.1-2.3 >2.3 0.7-1.2 
Creatinine (Female) – mg/dL  1.0 – 1.7 1.8 – 2.0 >2.0 0.5 - 0.9 
Calcium (hypocalcemia) – 
mg/dL  8 - <LLN  7.5 – 7.9 <7.5 8.7 - 10.3 
Calcium (hypercalcemia) – 
mg/dL  ULN - 10.8  10.9 – 11.4 >11.4  8.7 - 10.3 
CK-U/L  309-1000  1001 -1500  >1500  39-308 
Albumin (hypoalbuminemia) – 
g/dL  2.8 – 3.4 2.5 – 2.7 < 2.5  3.5 - 5.2 
AST – U/L (Male)  40-97 98-195 >195  <40   
AST – U/L (Female)  32-77 78-155 >155  <32  
ALT – U/L (Male)  41-100 101-200 >200  <41   
ALT – U/L (Female)  33-80 81-160 >160  <33 
Alkaline phosphatase – IU/L 
(Male)  131-260 261-390 >390  40-130  
 
Alkaline phosphatase – IU/L 
(Female)  106-210 211-315 >315  35-105 
Total Bilirubin (serum) – mg/dL  1.3-1.5 1.6-1.9 >1.9 0 - 1.2 
Direct Bilirubin – mg/dL  NA NA NA 0.0-0.2 
Chloride –mEq/L 
(hypochloremia)  NA NA NA  
96-108 
Chloride –mEq/L 
(hyperchloremia)  NA NA NA 96-108 
CO2 –mEq/L   (hypo)  NA NA NA 20- 30 
CO2 –mEq/L (hyper)  NA NA NA 20- 30 
Total Protein – g/dL  5.5 - 5.9 5.0 - 5.4 <5.0 6.0 - 8.0 
Phosphorus - mg/dl   (hypo)  2.3-2.4 2.1-2.2 <2.0 2.5 – 4.5 
Phosphorus -mg/dl   (hyper)  NA NA NA 2.5 – 4.5 
Total Cholesterol -mg/dl  NA NA NA <201  
Triglycerides -mg/dl  NA NA NA <151  
HDL – mg/dl  NA NA NA >65 F       >55 M  
Protocol: G03-52-01.001                    Version 3.0 
 September 7, 2021 
 ______________________________________________________________________________________________________  
Ology Bioservices, Inc.  94 Proprietary  
  Laboratory Adverse Events* Mild  Moderate  Severe  ICON Normal Lab 
Values  (Grade 1)  (Grade 2)  (Grade 3)  
LDL Direct – mg/dl  NA NA NA <130  
Hemoglobin (Male) – g/dL  11.2 - 12.2 10.0 – 11.1 <10.0  12.3-17.3 
Hemoglobin (Female) – g/dL  9.8 - 10.8 8.5 - 9.7 <8.5 10.9 - 14.6 
WBC Increase – cell/mm3 10,001 – 15,000  15,001 – 20,000  > 20,000  4,000 -10,000  
WBC Increase – cell/mm3 
(African America Males)  9,001 – 14, 000 14,001 – 19, 000  >19,000  4,000- 10,000 
WBC Increase – cell/mm3 
(African American Females)  11,001 – 15,000  15,001 – 20,000  >20,000  4,000- 10,000 
WBC Decrease – cell/mm3 2,500 – 3,999  1,500 – 2,499  < 1,500  4,000 -10,000  
WBC Decrease – cell/mm3 
(African American Males)  2,200 – 2,499 1,200 – 2,199 <1,200  4,000- 10,000 
WBC Decrease – cell/mm3 
(African American Females)  2,200 – 2,499 1,500 – 2,199 <1,500  4,000- 10,000 
Neutrophils Decrease – cell/mm3 1,300 – 1,699  1,000 – 1,299  < 1,000  1,700 -7,000  
Neutrophils Decrease – cell/mm3 
(African American Males)  1,000 – 1,299 800 - 999 <800  1,700- 7,000  
Neutrophils Decrease – cell/mm3 
(African American Females)  1,100 – 1,299 1,000 – 1,099 <1,000  1,700- 7,000  
Platelets Decreased – 10^3/mm3 120 – 149 100 – 119 <100  150-400 
Hematocrit (Male) - % 33.0 -36.1 29.8 - 32.9 < 29.8  36.2-51.1 
Hematocrit (Female) - %  29.5 - 32.6 26.0 – 29.4 < 26.0  32.7 - 43.5 
RBC (Male) – x 106/uL   3.9 - 4.1 3.4 - 3.8 < 3.4  4.2-5.8 
RBC (Female) – x 106/uL   3.5 - 3.7 3.0 - 3.4 < 3.0  3.8 - 5.8 
Lymphocytes - cell/mm3 
decrease  600- 799 500 – 599 < 500  800 - 3600  
Monocytes – cell/mm3     
increase  1001- 2000  2001- 3000  >3000  100 - 1000  
Eosinophils - cell/mm3     
increase  871 - 950 951 - 1700  >1700  60- 870 
Basophils - cell/mm3       increase  101 - 300 301 - 800 > 800  10-100 
PT (prothrombin time) – seconds  11.1-12.1 12.2-13.2 >13.2  9.1 - 11.0 
PT INR (Prothrombin INR)  1.2-1.4 1.5-1.9 2.0 or higher  .9-1.1 
PTT (partial thromboplastin 
time) –seconds  34.1- 40.8 40.9- 47.6 >47.6  22 - 34 
Urine  
Protein  1+ 2+ >2+ Neg.  
Glucose  1+ 2+ >2+ Neg.  
Blood (microscopic) - red blood 
cells per high power field 
(rbc/hpf)**  5-10* 11-50* >50 and/or 
gross blood** <5* 
 
 
  